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Angiogenesis inhibition in glioblastoma: 
 
The discovery of angiogenesis inhibition
Blood vessels constitute the first organ in the embryo and form the largest network in our body. 
Small blood vessels consist only of endothelial cells, whereas larger vessels are surrounded by 
pericytes and smooth muscle cells. Blood vessels can grow in several ways: Vasculogenesis refers 
to the formation of blood vessels by endothelial progenitors and Angiogenesis refers to the 
physiological process through which new blood vessels form from sprouting from pre-existing 
vessels and subsequent stabilization of these sprouts. When dysregulated, the formation of 
new blood vessels contributes to numerous malignant, ischemic, inflammatory and infectious 
disorders1 and inducing angiogenesis is considered one of the six hallmarks of cancer2. Since its 
first description as an therapeutic target in oncology by Judah Folkman in 1971 angiogenesis has 
been extensively studied in numerous types of cancer3. Currently the “angiogenic switch”, when 
the balance between pro- and anti-angiogenic factors tilts towards a pro-angiogenic outcome, is 
considered a rate-limiting secondary event in multistage carcinogensis4. The accepted consensus 
is, that this pro-angiogenic outcome leads to a transition from dormant avascularized hyperplasia 
to outgrowing vascularized tumor. In the first classical description by Dr Folkman on targeting 
this angiogenesis, anti-angiogenic agents would have a direct effect on endothelial cell apoptosis, 
which lead to cessation of new blood vessel growth3. This process ideally would lead to less 
oxygen and nutrients to the tumor and ideally to tumor “starvation”. But as the understanding of 
angiogenesis advanced it became clear that there are more pathophysiological mechanisms that 
contribute to this phenomenon.
Targeting angiogenesis: The discovery of VEGF
After the discovery of anti-angiogenesis as a new anticancer strategy, several molecules that can 
induce blood vessel growth in various bioassays were identified. Those included fibroblast growth 
factor 1 (FGF1; also known as aFGF), bFGF, angiogenin and transforming growth factor-α 
(TGFα), but their role in the regulation of angiogenesis remained unclear5. In 1989, the isolation 
and cloning of vascular endothelial growth factor A (VEGFA, previously known as vascular 
permeability factor (VPF))67 was a major step forward in understanding angiogenic mechanisms. 
Several studies showed that VEGFA possessed strong angiogenic properties that made it an 
attractive target for anti- angiogenesis8. In 1993, Kim and colleagues identified monoclonal 
antibodies that can target and neutralize VEGFA and inhibit tumor growth in preclinical studies 
9. The authors were able to demonstrate that when they injected human rhabdomyosarcoma, 
glioblastoma or leiomyosarcoma cell lines into nude mice this monoclonal antibody inhibited 
the growth of the tumors, but had no effect on the growth rate of the tumor cells in vitro. This 
led to the production of the recombinant humanized VEGFA-specific monoclonal antibody 
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bevacizumab (Avastin; Genentech/Roche), which was approved in 2004 by the US Food and 
Drug Administration (FDA) for the first-line treatment of metastatic colorectal cancer 10. While 
it has been utilized in clinical practice for multiple indications since then, it is becoming clear 
that it has variable effectiveness in different types of cancer one of which being glioblastoma11.
Angiogenesis in glioblastoma
The prognosis of the malignant brain tumor glioblastoma multiforme remains poor. After 
surgical resection, the standard of care for patients with newly diagnosed glioblastoma and a 
good Karnofsky performance score is concurrent radiotherapy and temozolomide, followed by 
adjuvant temozolomide12. Despite this intensive treatment, no further improvements in outcomes 
have been documented since the introduction of radiotherapy–temozolomide therapy in 2005 
and the median survival remains around 15 months. Due to its highly vascularized nature, 
the malignant brain tumor glioblastoma was hoped to be an ideal target for anti-angiogenic 
therapies like bevacizumab. In the first trials with bevacizumab in glioblastoma, enthusiasm was 
generated due to the radiographic response to this treatment, meaning the reduction in contrast 
enhancement on MRI, next to the reduction in tumor associated edema but unfortunately it 
did not correlate with the tumor response13,14. Two phase III trials in 2014 showed that adding 
bevacizumab to standard chemoradiotherapy only improved progression free survival without 
any effect on overall survival15,16. Additionally, a meta-analysis of randomized controlled trials 
in the recurrent setting of bevacizumab combined with chemotherapy showed an effect only 
on progression-free survival17. Nonetheless bevacizumab continues to be used in some settings, 
especially in recurrent tumors that have failed standard therapies and/or that do not qualify for 
targeted therapies. This lack of benefit in randomized trials, while clear benefit in the perception 
of clinicians due to the clear radiographic response and the reduction of tumor associated 
edema that improved patients clinical status, has resulted in increased effort in continuing the 
investigation of the mechanisms of antiangiogenic therapy with the goal to identify individual 
patients that would benefit most from this treatment.
Understanding the mechanism of failure
Because of the failure to find survival benefit after treatment with bevacizumab in phase III 
trials, increased effort into the understanding the mechanisms underlying this resistance has been 
undertaken. As the understanding of angiogenesis advanced it became clear that there are more 
pathophysiologic mechanisms that contribute to this phenomenon, such as vascular co-option, 
vasculogenesis, and vascular mimicry with all distinct mechanisms and cell signaling pathways 
that all play important roles in resistance to anti-angiogenic treatment. Although a minority 
of tumors seems to be intrinsically non-responsive to anti-angiogenic therapy, most tumors 
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employ evasive resistance mechanisms after an initial response phase. These evasive mechanisms 
that glioblastoma use include activation or upregulation of alternative pro-angiogenic signaling 
pathways within the tumor, recruitment of bone marrow derived pro-angiogenic cells, increased 
pericyte coverage of the tumor vasculature and activation and enhancement of invasion18. 
Although induction of angiogenesis is accepted as an hallmark of cancer, it is important to realize 
that the primary effect of anti-VEGF therapy is not cytotoxic and there is no evidence that 
bevacizumab directly induces glioma cell death. The main effect is rather pruning of abnormal 
tumor vasculature witch leads to vascular normalization 19. The resulting hypoxia that is 
exacerbated by these therapy most likely initiates a cascade of events that ultimately does not 
stop tumor growth with the current anti-angiogenic agents. Additionally, anti-VEGF therapy 
only blocks a single growth factor in a complex process of angiogenesis and thus only one aspect 
of the highly heterogeneous glioblastoma micro-environment in the setting of multiple events 
that contribute to angiogenesis and tumor growth. As mentioned earlier there are multiple stages 
within the tumor microenvironment that lead to blood vessel growth that are dependent on 
several other growth factors and are therefore most likely not affected by just one treatment20. 
This has led to an increased focus on the tumor microenvironment and the way treatment 
resistance mechanisms are being employed.
Central hypothesis
Despite these encountered difficulties and complexity of the tumor micro-environment, I am 
convinced that anti-angiogenic therapy for glioblastoma can be very effective when the right 
angiogenesis inhibitor and combination treatment is found. This has led to the central hypothesis: 
Angiogenesis inhibition is an effective treatment for patients with glioblastoma. The goal 
is to be able to identify patients that will benefit the most from this treatment and find research 
models that can answer the question which evasive mechanisms glioblastoma uses in the tumor 
micro-environment to become resilient to anti-angiogenic therapy and find treatment modalities 
to overcome this resistance.
To test this central hypothesis, I have generated five sub-hypotheses, which are described below 
and form the topic of investigation of the five chapters.
In chapter 1, I tested the hypothesis that radiation increases VEGF secretion in glioblastoma cell 
lines. In this in vitro study, I will measure the VEGF secretion by ELISA in glioblastoma cell 
lines. The combination of an angiogenesis inhibitor and radiation is possibly a more effective 
treatment. In chapter 2, I tested the hypothesis that 
the molecular profile by TCGA classification can predict response to bevacizumab in glioblastoma 
patients. Using a retrospective approach, I will analyze analyze the response to bevacizumab in 
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patients with recurrent glioblastoma. The goal is to identify patients that are most likely to 
respond to this treatment. In Chapter 3, we tested the hypothesis
that brain tumor stem cells in glioblastoma can form endothelial cells. In this in vitro and in vivo 
study, we will analyze an alternative way in which glioblastoma can form blood vessels. This may 
explain why anti-angiogenic therapy has variable effect. In Chapter 4, I tested the hypothesis 
that brain tumor stem cells in glioblastoma can be studied in an organotypic “explant” culture 
system. In this in vitro study, I aim to find a clinically relevant model to study brain tumor 
stem cells in the tumor micro-environment. In Chapter 5, I tested the hypothesis that Notch 
inhibition inhibits brain tumor stem cells and angiogenesis in an organotypic “explant” model 
of glioblastoma. In this in vitro study, our aim is to inhibit brain tumor stem cells in a clinical 
relevant model by using a known inhibitor of neural stem cells. This can potentially be used to 
overcome the resistance to the more commonly used angiogenic inhibitors.
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Objective: Postoperative radiotherapy is standard treatment for patients with a 
glioblastoma multiforme (GBM). However, a GBM is radioresistant and almost 
always recurs, even after a high dose of radiation. A GBM is characterized by its 
extensive neo-angiogenesis, which can be attributed to the high levels of vascular 
endothelial growth factor (VEGF). The scope of this study is to investigate the 
VEGF secretion by GBM cells with different radiosensitivity after irradiation.
Methods: Three human GBM cell lines (U251, U251-NG2 and U87) were 
irradiated with single doses of 0, 5, 10 and 20 Gy of γ-rays from a 137Cs source. 
VEGF levels in medium were measured by ELISA at 24, 48 and 72 h after 
radiation. Cell survival was measured by the XTT assay 7 days after irradiation.
Results: Following single dose radiation, the VEGF levels showed a dose dependent 
increase in U251, U251-NG2 and U87 glioma cells. Both base-line and radiation-
enhanced VEGF levels were about 10-fold higher in U87 compared to U251 and 
U251-NG2 cells. In addition, in the XTT assay, the U87 was more radioresistant 
than both U251 and U251-NG2 cell lines (dose modifying factor (DMF) 1.6 
and 1.7 resp.).
Conclusion: Irradiation enhanced VEGF secretion in all three tested glioma cell 
lines (up to eight times basal levels). It is tempting to associate the radiation-
enhanced VEGF secretion with an increased angiogenic potential of the tumor, 
which may be a factor in radioresistance.A
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Introduction
The mean survival time of patients suffering from the very malignant GBM is 1 year. In addition 
to operation the standard treatment consists of radiotherapy. Unfortunately local recurrence 
occurs in more than 90% of patients.
In the progression from low-grade tumors to more anaplastic tumors, gliomas show an increasing 
vessel density. The final transition to glioblastoma is marked by a characteristic endothelial 
proliferation and further increased vessel density, which often takes the form of glomeruloid 
vascular structures. This so called ‘angiogenic switch’ is associated with an up-regulation of VEGF 
and induction of its tyrosine kinase receptors flt- 1 and flk-1/KDR in endothelial cells [1]. Indeed 
significantly elevated levels of VEGF were found in the tissue and cyst fluid of glioblastomas and 
VEGF concentration clearly correlated with the vascularity of these glioblastomas [2]. Even in 
tumor cells infiltrating the surrounding brain tissue, a high expression of VEGF was found [3].
Extensive studies on VEGF and its receptors over the past 10 years have revealed that this system 
is a major regulator for angiogenesis [4]. VEGF has also been reported to have direct stimulatory 
growth and survival effects on neurons and glial cells [5]. Furthermore, VEGF has been shown to 
act as a survival factor for several tumor cells as well as normal cells by protecting against apoptosis-
inducing treatments, such as chemotherapy and irradiation [6]. With respect to endothelial cells, 
VEGF reduced the damaging effects of irradiation which may limit the vascular damage induced 
by radiotherapy [7–9]. Therapeutic options for glioblastoma multiforme treatment might be 
present with the observation that blocking VEGF by a monoclonal antibody in a heterotopic 
mice tumor model led to a reduced tumor growth [10]. Inhibition of the VEGF receptor, Flk-1, 
also induced complete inhibition of established glioblastoma xenografts [11].
The observation that serum VEGF is increased after
radiotherapy in brain tumor patients [12], suggests that the VEGF pathway is activated by 
radiation. In fact, Gorski [7] showed that in a number of human tumor cell lines a single dose of 
10 Gy irradiation induced enhanced VEGF secretion after 24 h. The enhanced VEGF secretion 
by surviving tumor cells may increase survival by decreasing apoptosis, stimulating proliferation 
and increasing angiogenic potential [6–9]. These factors may all contribute to the high vascularity 
as well as the high radioresistance of glioblastoma multiforme.
To establish whether enhanced VEGF secretion after irradiation is a general response of GBM 
cells, we studied the VEGF secretion in response to irradiation of two commonly used GBM cell 
lines, one with a high basal level of VEGF production (U87) [7] and one with a low basal VEGF 
level (U251) [13]. Additionally, the U251 GBM cell line transfected with the proteoglycan 
NG2 (U251-NG2) was studied, since this cell line was shown to form highly vascular tumors, 
although the tumor is a low VEGF secretor [13].
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Methods
Cell culture and selection of NG2-expressing cells
U251 and U251-NG2 cells were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) (GIBCO Life Technologies, Paisley, Scotland), supplemented with 10% heat-
inactivated newborn calf serum, four times the prescribed concentration of essential 
amino acids, 2% glutamine, penicillin (100 IU/ml), and streptomycin (100 µg/ml). This 
was supplemented with geneticin disulfate (800 µg/ml) (Sigma, Dorset, UK) to select for 
neomycin-resistant clones.
U87 cells were maintained in Dulbecco’s modified Eagles’s medium (DMEM) (GIBCO Life 
Technologies, Paisley, Scotland), supplemented with 10% fetal calf serum, 2% glutamine, 
penicillin (100 IU/ml), and streptomycin (100 µg/ml).
Irradiation
Because only one of the three cell lines formed colonies, the clonogenic assay, which is the standard 
for determining radiosensitivity, could not be used. In order to compare the radioresistance of 
all three cell lines we used a proliferation-based assay (XTT assay), which is highly comparable 
to the clonogenic assay when the cells are allowed to undergo six cell division [14]. The three 
cell lines were radiated with γ-rays from a 137Cs source at a dose rate of about 0.8 Gy/min. After 
irradiation with 0, 2, 4, 6, or 8 Gy, the cells were plated in well plates (100 µL cell suspension, 
500 and 1000 cells per well). After 7 days, the number of living cells was determined by a 
proliferation XTT assay (Roche Molecular Biochemicals, Mannheim, Germany); linearity 
range absorbance [A492–A690 nm]: 0.5–2.5; minimal detection limit approximately 5000 
cells per well). In short, 50 µl of the substrate (sodium 3¢-[1-(phenylaminocarbonyl)-3,4-
tetrazolium]-bis  (4-meth-oxy-6-nitro) benzene sulfonic acid hydrate) was added and incubated 
for 4 h at 37 “C. The substrate is converted into an orange formazan dye only in metabolically 
active cells. The formazan dye is soluble in aqueous solutions and can be measured using a 
spectrophotometer. Growth inhibition curves were prepared by the relative growth based on the 
optical densities of treated and control wells and IC50 values were determined.
Measurement of VEGF levels
The cells were plated in six-well plates at 25% confluence and allowed to attach overnight. They 
were irradiated with 0, 5, 10 and 20 Gy using a 137Cs source. Conditioned medium was collected 
24, 48 or 72 h after irradiation and the number of cells in each well was determined using a 
hemocytometer. Debris was pelleted for 5 min at 2000 rpm and supernatant was collected and 
stored at –20 °C.
A dilution series sequence of the samples with the highest and lowest expected values of VEGF 
was first performed to determine the appropriate dilutions. VEGF levels were measured by 
ELISA using an ELISA- kit (Biosource International, Camarillo, California, USA) according 
to manufacturers guidelines and normalized to cell number in each well. Levels of VEGF were 
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expressed as pg/ml/106 cells. From the cumulative measured values the VEGF-secretions by day 
were calculated. All standards, controls and samples were performed in duplicate. All experiments 
were done in triplicate.
Data analysis
Differences were analyzed with the Student t test. P values below 0.05 were considered to be 
significant.
Results
Effect of irradiation on VEGF production in GBM cell lines
Following single dose radiation, the VEGF levels showed a dose dependent increase in 
both U251, U251- NG2 and U87 (Figure 1) (P < 0.05). Maximal increase was seen 72 
h post irradiation in all three GBM cell lines. The levels of VEGF showed an radiation-
induced increase after 24 h. A statistically significant increase (P < 0.05) in VEGF 
secretion was observed for each dose and each time point except for U251 and U251- 
NG2 treated with 5 Gy after 72 h (respective P 0.7998, P 0.6312), U87 treated with 5 
Gy after 24 h (P 0.8312) and U251 after 10 Gy and 72 h (P 0.0755). The highest levels 
of VEGF were found after 72 h in the medium of cells irradiated with 20 Gy (U251: 
16784, U251-NG2: 20992, U87: 112227 pg/ml/106 cells).
Of the three cell lines tested here, U87 produced the most VEGF both with and without 
irradiation (U87: 13.936 pg/ml/106 cells, U251; U251-NG2: 1422 and 1240 pg/ml/106 cells 
Figure 1. VEGF protein levels (pg/ml/106 cells) in U251 (white bar), U251-NG2 (grey bar) and U87 (black 
bar) conditioned medium after irradiation. Mean with standard errors of three separate experiments performed in 
duplo are shown. U87, U251 and U251-NG2 cells were plated in six-well plates at 25% confluence, allowed to 
attach overnight, and then irradiated with 0, 5, 10 or 20 Gy. Conditioned medium was collected every 24 h, and 
VEGF levels were normalized to cell number.
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after 24 Gy and no irradiation). U251 and U251-NG2 cells produced similar amounts of VEGF 
with and without irradiation. A dose dependent, radiation-induced, increase of VEGF was 
shown in these cell lines as well. This increase was already apparent after 24 h and maximum 
after 72 h.
The total VEGF-secretion per day showed a higher variability than the cumulatively measured 
values (Figure 2 A–C). The secretion of VEGF per day after a single dose of radiation was higher 
Figure 2. VEGF protein levels (pg/ml/106 cells) 
in U251 (a), U251- NG2 (b) and U87 (c) 
conditioned medium per day after irradiation. 
Mean with standard errors of three separate 
experiments performed in duplo are shown. 
VEGF-secretion by day was calculated from the 
cumulative data.
Figure 3. XTT assay of U251 (square), 
U87 (diamond) and U251- NG2 (triangle) 
(n = 4). The three cell lines were irradiated 
with 0, 2, 4, 6, and 8 Gy. After 7 days, the 
number of living cells was determined by a 
proliferation XTT assay. Growth inhibition 
curves were prepared by the relative growth 
based on the optical densities of treated and 
control wells from which IC50 values were 
derived.
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than without irradiation for most values of the three cell lines: U251, U251-NG2 and U87. The 
increase of VEGF secretion per day was up to eight times over control. Generally, the VEGF-
secretion per day increased in a dosedependant manner, with maximum increase after irradiation 
with a single dose of 20 Gy.
Sensitivity to irradiation of the GBM cell lines U87, U251 and U251-NG2
To determine the sensitivity of the three cell lines to irradiation a XTT assay was performed 
on all three cell lines. Growth inhibition curves were prepared by using the relative growth 
(see materials and methods) (Figure 3). U87 cells were more resistant to irradiation than either 
U251 cells or U251-NG2. U251 and U251- NG2 cells had similar sensitivities to irradiation. 
At the IC50 U87 cells were more resistant to irradiation than U251 and U251-NG2. The dose 
modifying factor (DMF) for U251 is 1.6 compared to U87 and the DMF for U251-NG2 is 
1.7 compared to U87.
Discussion
This study shows that radiation induces a dose-dependent increase in VEGF-secretion in three 
glioblastoma multiforme cell lines: U87, U251 and U251-NG2. The effect of radiation was 
most apparent after a single dose of 20 Gy. The increase in VEGF secretion per day was up 
to eight times for the three tested cell lines. It is unlikely that the measured increase in VEGF 
concentration in the conditioned medium does not reflect enhanced secretion. We did not find 
a decrease in cell number after irradiation, even after irradiation with 20 Gy (data not shown). 
Other studies also failed to demonstrate apoptosis or autophagy in a number of glioblastoma cell 
lines after irradiation [15]. Moreover, VEGF has been shown to reduce apoptosis after irradiation 
in human leukemia cells and in human and murine mammary adenocarcinoma cells [16–18].
Our results are similar to the results obtained by Gorski and coworkers on Lewis lung carcinoma 
(LLC) cells [7]. The LLC cells also showed a dose-dependent, time dependent increase in VEGF 
secretion after irradiation. The radiation-enhanced VEGF secretion has so far been shown 
in GBM cell lines (U87, T98, T9 RT2), a lung carcinoma cell line (LCC), an oesophageal 
adenocarcinoma (Seg-1), a squamous cell carcinoma (SQ20B), a melanoma cell line (U1) and 
primary astrocytes [7,19]. Irradiation has been shown to stimulate the VEGF promoter via 
multiple mitogen activated protein kinase (MAPK) dependent pathways in primary astrocytes 
and GBM cell lines [19]. Hypoxia seems not to be involved in this mechanism, since the hypoxia-
inducible factor HIF1α was not expressed after irradiation [19]. However, progression elevated 
gene 3 (PEG 3) may be involved in the observed enhancement of VEGF secretion, because 
irradiation activated the PEG-3 promoter via MAPK signalling in primary astrocytes and GBM 
cell lines [19]. In the glioblastoma cell lines T9 and RT2 the PEG-3 and VEGF expression 
correlated directly to their oncogenic potential [19].
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In the present study an XTT assay was performed on U251, U251-NG2 and U87 cells to 
assess the relative sensitivity to irradiation, in comparison with each other. U251 and U251-NG2 
showed similar sensitivity. At the IC50-level U87 cells were more resistant to irradiation than 
U251 and U251-NG2 (DMF: 1.6 and 1.7 resp.). These results are in concordance with the 
radiobiological parameters of U87 and U251 found by Haas- Kogan et al. in clonogenic assays 
[20].
Since U87 was most resistant to irradiation and had the highest basal VEGF secretion, this 
suggests that enhanced VEGF secretion is involved in radioresistance. Steiner et al. showed that 
the upregulation of VEGF leads to a downregulation of glioblastoma cell proliferation, which 
might explain the reduced radiosensitivity [21]. The role of VEGF in radioresistance is supported
by preclinical studies, in which GBM cell line cells were placed in a murine tumor model system 
and treated with radiotherapy in combination with anti-VEGF therapy [7]. A greater than additive 
effect was seen [7–9,22], which was independent of the degree of hypoxia [23]. The importance 
of irradiation induced enhanced VEGF- secretion in radioresistance was not studied so far. In 
further studies we plan to investigate the importance of the radiation-induced enhancement of 
VEGF secretion (e.g. U251 and U251-NG2) in an orthotopic mouse tumor model.
In conclusion, irradiation induces significant enhancement of VEGF-secretion which appears 
to be a general response in GBM cell lines. Therefore we speculate that the radiation-enhanced 
VEGF-secretion decreases apoptosis and increases angiogenesis, both leading to GBM 
radioresistance.
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Purpose The highly vascular malignant brain tumor glioblastoma (GBM) appears 
to be an ideal target for anti-angiogenic therapy; however, clinical trials to date 
suggest the VEGF antibody bevacizumab affects only progression-free survival. 
Here we analyze a group of patients with GBM who received bevacizumab treatment 
at recurrence and are stratified according to tumor molecular and genomic profile 
(TCGA classification), with the goal of identifying molecular predictors of the 
response to bevacizumab.
Methods We performed a retrospective review of patients with a diagnosis of 
glioblastoma who were treated with bevacizumab in the recurrent setting at our 
hospital, from 2006 to 2014. Treatment was discontinued by the treating neuro-
oncologists, based on clinical and radiographic criteria. Pre- and post-treatment 
imaging and genomic subtype were available on 80 patients. We analyzed time on 
bevacizumab and time to progression. EGFR gene amplification was determined by 
FISH. 
Results Patients with classical tumors had a significantly shorter time on bevacizumab 
than mesenchymal, and proneural patients (2.7 vs. 5.1 vs. 6.4 and 6.0 months 
respectively, p = 0.011). Classical subtype and EGFR gene amplification were 
significantly associated with a shorter time to progression both in univariate (p< 
0.001 and p = 0.007, respectively) and multivariate analysis (both p = 0.010).
Conclusion EGFR gene amplification and classical subtype by TCGA analysis are 
associated with significantly shorter time to progression for patients with recurrent 
GBM when treated with bevacizumab. These findings can have a significant impact on 
decision-making and should be further validated prospectively.
Keywords Bevacizumab · Classical · EGFR · Glioblastoma · Mesenchymal · 
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Introduction
Since its description in 1993 the monoclonal antibody against VEGF (bevacizumab) has been 
extensively studied [1, 2], and is in use for several cancer types. Due to its highly vascularized 
nature, glioblastoma was once considered an ideal target for anti-angiogenic therapies like 
bevacizumab (Avastin) [3]. However, data emanating from clinical trials as well as off trial experience 
have shown a modest and unsustained impact on disease progression. Two recent phase III trials 
showed that adding bevacizumab to standard chemo-radiotherapy in the upfront setting only 
improved progression-free survival with no overall survival benefit [4, 5]. A recent meta-analysis of 
randomized controlled trials of bevacizumab combined with chemotherapy in the recurrent setting 
also showed, an effect only on progression-free survival [6]. Nonetheless bevacizumab continues to 
be used in some settings, especially in recurrent tumors that have failed standard therapies and/or that 
do not qualify for targeted therapies. In view of increasing drug costs, the complications of the 
treatment and the lack of demonstrated survival benefit, identification of potential predictors of 
bevacizumab response, beyond common factors such as KPS could help guide treatment decisions 
[7].
Additional experience with bevacizumab has allowed for clarification of complications of 
treatment in GBM that include thrombocytopenia, cerebral hemorrhages, arterial thrombo-embolic 
events, proteinuria, hypertension, visceral perforation, and inhibition of wound healing [8–12]. 
Furthermore, as the experience with this therapy grew, a more invasive pattern of progression 
of GBM has been observed to develop while under anti-angiogenic therapy [13, 14]. A potential 
mechanism involving the inhibition of the HIF1α mediated hypoxic response in the tumor 
micro-environment has been proposed to underlie the more invasive or multifocal phenotype 
[15]. In light of these potential downsides, identifying which patients will benefit the most from 
bevacizumab treatment is crucial. We hypothesized that stratification by molecular profile, data that 
is increasingly available at many institutions, might provide a basis for prediction of treatment 
response, and eventually a rational parameter to be used for selecting patients to be treated with 
bevacizumab.
Recent large-scale genomic analyses have revealed patterns of molecular changes within tumor 
subclasses that harbor distinct underlying biology and clinical prognosis [16, 17]. Over the last 
decade or so, the TCGA (The Cancer Genome Atlas) classification was adopted by many centers, 
including ours. According to this schema, glioblastomas can be classified by transcriptomal features 
into classical, mesenchymal, neural or proneural subtypes that exhibit different gene mutation profiles, 
biological properties and treatment responses [17]. In addition, several well-known molecular 
markers such as IDH-1 mutation, EGFR amplification or mutation, and MGMT promoter 
methylation are often reported in GBM [18]. Molecular subtyping is increasingly incorporated into 
more traditional schemes, such as the latest WHO classification update [19]. The clinical challenge for 
the future will be to match treatment to the best molecular fit.
An earlier post-hoc analysis of the BELOB trial determined that tumors classified as “classical 
subtype” per TCGA criteria at first diagnosis, when treated with bevacizumab and CCNU at 
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recurrence), led to an improvement in progression free survival [20]. Notably this cohort had almost 
exclusively classical tumors. In this report we sought to determine if molecular subclasses of glioblastoma 
(determined at the time of recurrence) respond in a distinct manner to bevacizumab treatment when 
given at recurrence.
Methods
Patient selection
Patients with pathologically confirmed glioblastoma treated with bevacizumab (Genentech 
South San Francisco, California, United States) in the recurrent setting and for whom 
genomic subtype analysis according to TCGA criteria (classical, proneural, mesenchymal, 
and neural) was available, were retrospectively identified. The classification was performed soon after 
tissue acquisition, independently of treatment decisions, and confirmed by CB and JH. Patients 
meeting these criteria treated at our hospital between 2006 and 2014 were retrieved by a search of 
a prospectively collected brain tumor registry database. The research protocol was approved by the 
IRB. KPS, gender, age, date of death and other treatment modalities were collected.
Molecular data
All molecular data was determined at recurrence. EGFR amplification was determined by FISH 
analysis, EGFR VIII by immunostaining, and MGMT promoter methylation status by real-
time methylation specific PCR at our institution. IDH mutation analysis has been available on 
more recent cases but was not available on enough patients to do a meaningful analysis.
Nanostring analysis
Analysis of the Cancer Genome Atlas (TCGA) glioblastoma transcriptional subclasses was 
determined by using a semiquantitative gene expression profiling assay (Nanostring nCounter, 
Seattle, Washington, USA) based on 81 genes selected from the initial TCGA publication as 
described earlier [17, 21, 22]. Briefly, RNA from 192 GBM samples from TCGA was analyzed 
with codeset of 146 probes, including for 81 genes previously selected to distinguish TCGA 
expression subclasses. Raw codeset counts were normalized by a panel of GBM-invariant genes 
[22] and were used to generate centroids for four transcriptomal classes (proneural, classical, 
mesenchymal and neural) according to published classification by TCGA [17]. RNA was extracted 
from tumor tissue and assayed by the same Nanostring protocol and codeset. Patient sample RNA 
transcriptomal class assignments were assigned by the nearest TCGA class centroid by correlation.
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Outcomes
Our main outcome measurement was time to progression on bevacizumab, defined as the time from 
the start of bevacizumab treatment until clinical progression as determined by the treating neuro-
oncologist, and/or radiographic progression determined by RANO criteria [23]. Patients who 
stopped bevacizumab treatment for reasons other than progression were censored. In addition 
overall survival and time on bevacizumab were assessed. Bevacizumab was discontinued due to 
progression, toxicity or complications as determined by the individual treating neurooncologist. 
Since the determination of clinical progression is often based on MRI progression, we analyzed 
MRI changes during bevacizumab treatment. It is well known that bevacizumab can diminish 
gadolinium enhancement after contrast [24], so we included flair changes and multifocality changes 
in addition to contrast enhancement [23]. Radiographic progression while on bevacizumab was 
noted as either an increase in tumor volume on FLAIR or T1 weighed images with contrast or as 
the development of an additional lesion(s) (multifocal disease) on post treatment MRI, compared 
to pretreatment MRI. We included both clinical and radiographic progression in our outcomes 
evaluation, because clinical deterioration in this patient population is often attributed to disease 
progression in the absence of clear etiology such as seizures, even though it is not always extensively 
investigated. Other reasons for deterioration such as cognitive decline related to previous therapy 
(e.g. radiation), side effects of other medications or delirium, can therefore not be fully excluded.
Multifocal change
Since a more invasive behavior of GBM has been described in the setting of treatment with 
bevacizumab, we specifically looked at multifocal change [13]. We defined multifocal change as the 
appearance of a discrete new lesion (on FLAIR or T1 + contrast sequences), which have no visible 
connection to the existing lesion.
Volumetric analysis
Volumetric measurements were obtained using iPlan Net 3.0.0 software (BrainLAB AG, Germany 
2009). Regions of interest (ROIs) were manually drawn by two neurosurgeons (KEH and YE) on each 
post-contrast axial T1-weighted and FLAIR image and used to compute the volume of the tumor in 
cubic centimeters. Tumor volume was measured on the MRI scan nearest to the start date and end 
point of bevacizumab treatment.
Statistical methods
Statistical testing was designed and performed by statisticians (JZ and KP). Associations between 
patient characteristics and MRI features with genomic subtype and molecular profile were examined 
using Fisher’s exact test and the Kruskal–Wallis test. Time on bevacizumab was compared between 
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genomic subtypes using Kruskal–Wallis test since all patients stopped using bevacizumab at our last 
follow- up. The Kaplan–Meier method and Cox proportional hazards regression models were fit to 
evaluate associations of genomic subtype, age, gender, KPS, molecular profiles with time to progression 
on bevacizumab and overall survival (OS). Death was not a competing risk in the analysis of pro- 
gression considering that all deaths occurred after stopping bevacizumab. Considering the number 
of patients who had undetermined EGFR amplification (19%) or EGFR VIII expression (48%), 
undeterminate status were treated as a separate group in above analyses.
A p value less than 0.05 was considered statistically sig-nificant. All analyses were performed in 
software packages SAS 9.4 (SAS Institute Inc., Cary, NC, USA), and R version 3.1 (The R 
Foundation for Statistical Computing).
Results
Patient characteristics
This study identified 84 glioblastoma patients with transcriptomally-defined TCGA subtype 
who received bevacizumab for recurrent tumor. Four patients were excluded due to insuffcient 
documentation of treatment and MRI dates. Table 1 describes characteristics of the 80 patients: 
21% classical, 29% mesenchymal, 25% proneural and 5% neural. Clinical or radiographic 
progression was found in 65 patients. In 15 patients bevacizumab was stopped for reasons other 
than clinical or radiographic progression. Those included: wound dehiscence, nephrotoxicity, 
DVT, bowel perforation and intracranial hemorrhage. Among those patients, 8 had a mesenchymal 
subtype, 3 had a classical, 2 had a proneural and 2 had a neural subtype. Age and KPS were 
similarly distributed across the different genomic subtypes. The median time on bevacizumab was 
4.6 months (range 0.2–32.2). The pre-treatment MRI was performed within 66 days (interquartile 
range (IQR6–16) prior to bevacizumab start, and post-treatment MRI was performed between 75 
days prior to bevacizumab discontinuation and 209 days post bevacizumab end (IQR 2 prior—3 
post). Although this is a wide range, most were done within a few days of treatment start and 
discontinuation; and time of MRI did not differ significantly among
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the different subtypes (p = 0.783). The majority of patients who progressed received other therapies 
during and after stopping treatment with bevacizumab, which were not statistically different amongst 
the different subtypes (Supplementary Table S1).
Fig. 1 Time to progression on bevacizumab by a TCGA subtype b EGFR amplification status. Kaplan–Meier curve 
for time to progression on bevacizumab stratified by TCGA subtype (a) and EGFR amplification status (b)
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Classical glioblastomas have the shortest time on bevacizumab and a higher 
risk of progression
Time on bevacizumab was significantly shorter for the classical GBMs compared to the 
mesenchymal, neural and proneural subgroups (2.7 vs. 5.1, 6.4 and 6.0 months respectively, p= 
0.011, Table 1). The classical subgroup also had a higher risk of progression than other subgroups in 
univariate analysis (p < 0.001, Fig. 1a; Table 2) and remained significant in multivariate analysis 
Table 2 Time to progression on bevacizumab (N = 80)
Univariate analysis Multivariate analysis
HR (95% CI) p value HR (95% CI) p value
Age at treatment start 1.00 (0.97, 1.02) 0.829
Baseline flair MRI volumea, cm3 1.01 (0.97, 1.04) 0.742
Gender 0.854
F 1
M 1.05 (0.64, 1.73)
Nanostring < 0.001 0.010
Classical 1 1
Mesenchymal 0.26 (0.13, 0.52) 0.39 (0.17, 0.88)
Neural 0.22 (0.06, 0.77) 0.23 (0.06, 0.85)
Proneural 0.43 (0.23, 0.82) 0.76 (0.29, 1.95)
KPS 0.805
50–70 1
80–100 1.07 (0.64, 1.76)
MGMT methylated status 0.725
No 1
Yes 1.29 (0.66, 2.53)
Unknown 1.16 (0.66, 2.04)
EGFR gene amplified 0.007 0.010
No 1 1
Yes 2.39 (1.36, 4.18) 4.00 (1.63, 9.77)
Unknown 1.32 (0.67, 2.61) 2.25 (1.03, 4.92)
EGRF VIII status 0.014 0.001
Absence 1 1
Presence 0.67 (0.34, 1.32) 0.35 (0.16, 0.79)
Unknown 0.44 (0.25, 0.78) 0.33 (0.17, 0.62)
HR hazard ratio
Progression on bevacizumab was defined as either clinical or radiologic progression (N = 65)
aThe increment of hazard ratio estimates is every 10-unit increase in these size measurements
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(p = 0.010). Of note, in the mesenchymal group 3 patients (10.3%) remained on bevacizumab 18 
months or more versus none in the proneural and classical groups, suggesting some durability to this 
treatment in a select subgroup of patients.
EGFR amplification is associated with a shorter time to progression
EGFR amplification was determined in 85% of the patients and in 43% (28/65) of them the gene 
was amplified. As expected, the amplified EGFR gene was significantly more often present in the 
Fig. 2 Overall survival (OS) by a TCGA subtype and b EGFR amplification status. Kaplan–Meier survival curve 
stratified by TCGA subtype (a) and EGFR amplification status (b)
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classical subtype tumor (p < 0.001). Interestingly, amplified EGFR status was associated with a 
higher risk of progression on bevacizumab (p = 0.007, Fig. 1b; Table 2). This finding remained 
significant after controlling for genomic subtype and EGFR VIII expression in multivariate analysis 
(p = 0.010, Table 2). MGMT promoter methylation status was available in 69% of the patients and was 
more often unmethylated in patients with mesenchymal tumors (p= 0.011) but was not associated with 
a risk of progression (p = 0.725, Tables 1, 2).
Overall survival by EGFR amplification status and subtype
All but 1 of the patients in this cohort died. The median overall survival from treatment initiation 
was 7.9 months (95% CI 6.5–11.4). Consistent with time to progression, patients with either the 
classical phenotype or EGFR-amplified tumors seemed to do worse although these differences were 
not statistically significant (Fig. 2a, b). These results should be interpreted with caution in light of the 
additional treatments that these patients received.
No significant difference in tumor volume and multifocal change between 
subtypes
Large differences in tumor volume and in volume changes were noted in the different subtypes 
on T1 with contrast and FLAIR MRI images, but none reached statistical significance (Table 1). 
Multifocal change while under bevacizumab treatment was a relatively common finding (92%) but it was 
not different among the subtypes (Table 1).
Discussion
Our data suggest that glioblastomas that exhibit EGFR amplification or classical TCGA 
subtype are associated with a shorter time to progression on bevacizumab in the recurrent setting, 
in comparison to tumors with a proneural, neural and mesenchymal subtype or tumors without EGFR 
amplification. Patients with a classical subtype had a median time to progression of 2.8 months (95% 
CI 1.6–4.8) and in patients with EGFR amplified tumor, the median time to progression was 
3.7 months (95% CI 1.6–5.6). A worse outcome in EGFR-amplified and classical tumors was 
statistically significant on both univariate and multivariate analysis. No difference in tumor volume 
change or multifocal change while on bevacizumab was observed among the different tumor subtypes. 
Our results therefore suggest that this treatment may be better reserved for patients without EGFR 
amplification or with a non-classical subtype.
This study has several limitations: the two most significant being the retrospective nature of the 
analysis and the different and intensive treatments that patients received in addition to bevacizumab. 
Even though receiving additional treatments was similarly distributed across the tumor subtypes, a 
treatment-related potential bias cannot be excluded. Another limitation is the fact that the decision 
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to discontinue bevacizumab was often made on clinical grounds, as determined by the treating neuro-
oncologist, and not necessarily always with clear evidence for radiographic progression. However the 
high volume of glioblastoma patients treated at MSKCC and the fact that treatment decisions 
are made in a multidisciplinary setting (e.g. tumor board) increases the uniformity of decision making 
across patients. Strengths of the study include the objective nature of the radiographic analysis and 
the fact that the treating physicians were blinded to the tumor subtype at the time of treatment. Another 
strength of the study is that the tissue analysis was done on the recurrent tumor. This is especially 
important since there are many genetic and epigenetic differences between the primary neoplasm 
at diagnosis and the recurrent tumor [25]. An important recent initiative to understand this process 
better is the Glioma Longitudinal Analysis (GLASS) Consortium, which has been initiated to better 
understand the recurrence process and, in doing so, discover vulnerabilities that can be used for 
therapeutic intervention [26].
Our finding of a strong association between EGFR amplification and a shorter time to 
progression on bevacizumab is novel. The fact that EGFR amplification alone also resulted in a 
statistically powerful difference in terms of progression on bevacizumab is important, as it is more 
readily determined by a simple widely available test (FISH analysis). TCGA class analysis might 
not be routinely available in every institution. Also, EGFR amplification is usually retained from 
primary to recurrent tumors [27]. It is interesting to note that some patients with mesenchymal 
tumors, that were all MGMT unmethylated, seemed to do better on bevacizumab in this study. 
In a few cases some patients managed to stay on this treatment for more than 18 months, suggesting 
that the mesenchymal subtype may be more suitable to this treatment. This is especially promising 
since this subtype was shown to have the worst prognosis and recurrent tumors have often shown a 
switch to this subtype [28]. Although the mesenchymal subtype has the most “angiogenic” signature, 
thus was expected to respond most to bevacizumab, a recent report suggested that the proneural subclass 
benefited more from bevacizumab treatment in the upfront setting. In a retrospective analysis of 
the AvAglio trial, patients with wild type IDH proneural glioblastomas had a significant overall 
survival advantage of 17.1 versus 12.8 months versus placebo. The underlying mechanism of 
this preferential response is still unclear [29]. Interestingly, another phase II trial, that looked at 
hypofractionated stereotactic radiotherapy schedule with temozolomide and bevacizumab for newly 
diagnosed glioblastomas, found that proneural tumors did worse than the other subtypes, although 
this did not reach statistical significance for overall survival [21]. As mentioned earlier, molecular 
analysis of patients in the BELOB trial led the authors to conclude that in the recurrent setting 
classical tumors had the longest progression free survival when treated with bevacizumab and CCNU 
[20]. Even though this patient cohort was much more uniform, the tissue analysis was done on the 
original tumor and not in the recurrent setting as in our study which is known to change [25]. By far 
the most tumors (68%) in the BELOB trial were classical and other types were grouped as “non-
classical” because of low numbers, which may have impacted the results. Also their findings were 
only in the combination treatment group and not bevacizumab alone. The finding of mesenchymal 
tumors responding for an extended period of time to bevacizumab in the recurrent setting has not 
been reported previously, to our knowledge. It has become evident in recent years that bevacizumab 
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treatment is not without risk, in particular from wound breakdown and the possibility of inducing 
a more infiltrative/aggressive tumor after treatment [14]. Our analysis suggests that bevacizumab should 
be considered more carefully in classical and EGFR-amplified tumors and may be more beneficial 
for mesenchymal, neural and proneural tumors. Nevertheless bevacizumab remains one of the few 
options available to patients with recurrent tumors that have failed standard of care and available trials. 
Neuro-oncologists have thus maintained this drug in their armamentarium, especially since it also offers 
a significant anti-edema activity. It is therefore highly relevant to investigate potential predictors 
of high failure risk. Further work will be needed to identify a potential mechanistic antagonism in 
the context of EGFR amplification that might explain these results. Alternatively, confounding factors 
such as the stage at which bevacizumab is used in these tumors, specific prior or concomitant treatment 
regimens may contribute to the worse results seen in this group.
Conclusion
Classical subtype and EGFR-amplified glioblastomas show a worse response to bevacizumab in the 
recurrent setting. Additional investigations are required to further validate this finding as well as to 
investigate the mechanistic basis for bevacizumab propensity to fail in the setting of amplified 
EGFR.
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Supplementary table S1: additional treatment with avastin stratified by (a) TCGA subtype and (b) EGFR 
amplification status
Classical Mesenchymal Proneural p Value
n (%) n (%) n (%)
Number of treatment pre bevacizumab
0 1 (5%) 1 (5%) 0 (0%) 0.453
1 5 (26%) 5 (24%) 5 (22%)
2 7 (37%) 9 (43%) 10 (43%)
3 4 (21%) 6 (29%) 3 (13%)
4 2 (11%) 0 (0%) 5 (22%)
Number of treatment during bevacizumab
0 11 (58%) 9 (43%) 9 (39%) 0.588
1 5 (26%) 10 (48%) 10 (43%)
2 2 (11%) 2 (10%) 4 (17%)
3 1 (5%) 0 (0%) 0 (0%)
Number of treatment post bevacizumab
0 10 (53%) 13 (62%) 17 (74%) 0.133
1 5 (26%) 7 (33%) 3 (13%)
2 4 (21%) 0 (0%) 1 (4%)
3 0 (0%) 1 (5%) 1 (4%)
4 0 (0%) 0 (0%) 1 (4%)
EGFR amplification status
No Yes Unknown p value
Number of treatment pre bevacizumab
0 0 (0%) 2 (9%) 0 (0%) 0,298
1 8 (30%) 6 (26%) 1 (8%)
2 10 (37%) 7 (30%) 9 (69%)
3 5 (19%) 5 (22%) 3 (23%)
4 4 (15%) 3 (13%) 0 (0%)
Number of treatment during bevacizumab
0 11 (41%) 11 (48%) 7 (54%) 0,785
1 13 (48%) 7 (30%) 5 (38%)
2 3 (11%) 4 (17%) 1 (8%)
3 0 (0%) 1 (4%) 0 (0%)
Number of treatment post bevacizumab
0 20 (74%) 15 (65%) 5 (38%) 0,109
1 5 (19%) 5 (22%) 5 (38%)
2 1 (4%) 3 (13%) 1 (8%)
3 0 (0%) 0 (0%) 2 (15%)
4 1 (4%) 0 (0%) 0 (0%)
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Glioblastoma (GBM) is among the most aggressive of human cancers1. A key 
feature of GBMs is the extensive network of abnormal vasculature characterized 
by glomeruloid structures and endothelial hyperplasia2. Yet the mechanisms 
of angiogenesis and the origin of tumour endothelial cells remain poorly 
defined3–5. Here we demonstrate that a subpopulation of endothelial cells within 
glioblastomas harbour the same somatic mutations identified within tumour cells, 
such as amplification of EGFR and chromosome 7. We additionally demonstrate 
that the stem-cell-like CD1331 fraction includes a subset of vascular endothelial-
cadherin (CD144)-expressing cells that show characteristics of endothelial 
progenitors capable of maturation into endothelial cells. Extensive in vitro and 
in vivo lineage analyses, including single cell clonal studies, further show that a 
subpopulation of the CD1331 stem-like cell fraction is multipotentand capable of 
differentiation along tumour and endothelial lineages, possibly via an intermediate 
CD1331/CD1441 progenitor cell. The findings are supported by genetic studies 
of specific exons selected from The Cancer Genome Atlas6, quantitative FISH 
and comparative genomic hybridization data that demonstrate identical genomic 
profiles in the CD1331 tumour cells, their endothelial progenitor derivatives 
and mature endothelium. Exposure to the clinical anti-angiogenesis agent 
bevacizumab7 or to a γ-secretase inhibitor8 as well as knockdown shRNA studies 
demonstrate that blocking VEGF or silencing VEGFR2 inhibits the maturation 
of tumour endothelial progenitors into endothelium but notthe differentiation 
of CD1331 cells into endothelial progenitors, whereas γ-secretase inhibition or 
NOTCH1 silencing blocks the transition into endothelial progenitors. These data 
may provide new perspectives on the mechanisms of failure of anti-angiogenesis 
inhibitors currently in use. The lineage plasticity and capacity to generate tumour 
vasculature of the putative cancer stem cells within glioblastoma are novel findings 
that provide new insight into the biology of gliomas and the definition of cancer 
stemness, as well as the mechanisms of tumour neo-angiogenesis.A
bs
tr
ac
t
Glioblastoma stem-like cells give rise to tumour endothelium.
4
51|
Blood vessels within GBM express a variety of markers, including CD31 and CD105 (also known 
as PECAM1 and ENG, respectively); CD105 is a proliferation-associated molecule expressed in 
angiogenic endothelium9. Quantitative analysis of 16 GBM specimens by fluorescence-activated 
cell sorting (FACS) and immunohistochemistry showed that more than 70% of CD1051 cells 
co-express CD31 (Fig. 1a, b), VEGFR2 (also known as KDR) and von Willebrand factor (also 
known as VWF), exhibit endothelial morphology, and labelling by DiI-AcLDL (1,1'-dioctadecyl-
3,3,3',3'-tetramethyl-in docarbocyanine perchlorate-labelled acetylated low density lipoproteins, 
ref. 10), suggesting an endothelial phenotype (Supplementary Fig. 1a). On average, ,5% of the 
total cell population expressed CD31 in normal brain and GBM specimens (n 5 7), whereas 
CD1051 cells were essentially absent in normal brain (Supplementary Fig. 1b). CD1051 cells 
were also isolated by FACS from fresh GBM specimens and injected with a collagen matrix11 
into the flank of NOD-SCID mice. The resulting implants were composed of a network of 
vascular channels of human origin, expressed CD105 and CD31 and showed evidence of uptake 
of systemically injected lectin (Fig. 1c).
Whereas endothelial cells in GBMs are often classified as ‘‘hyperplastic’’2, the abnormal blood vessel 
architecture, the distinct gene expression profiles12 and the selective emergence of abnormal vessels 
in GBMs versus lower grade gliomas2 suggest a more complex ontogeny of GBM endothelium. 
We performed quantitative fluorescence in situ hybridization (FISH) analyses for EGFR and 
chromosome 7 (ref. 13) on CD1051 cells isolated by FACS and on sections of the corresponding 
GBM parent tumour (Fig. 1d, e and Supplementary Fig. 2). The proportion of CD1051 cells 
harbouring $3 copies of the EGFR amplicon or the centromeric portion of chromosome 7 was 
comparable to the proportion of tumourcells with the same aberrations (Supplementary Table 
1a). We also performed quantitative PCR (qPCR) for three segments of the EGFR amplicon 
(exons 4, 9 and 11), known to be mutated at high frequency according to data from The Cancer 
Genome Atlas6. The data demonstrate a similar copy number in the CD1051 cells and the 
corresponding parenttumour(Supplementary Table 1b) and indicate thata proportion of tumour 
endothelial cells within GBM is in fact neoplastic. CD133 is a cell surface glycoprotein used 
extensively as a marker of putative cancer stem cells (CSCs) but also expressed in haematopoietic 
stem cells14–18. Although the specific identity and definition of CSCs remains a matter of 
debate, we proposed that the CD1331 fraction may be related to the endothelial differentiation 
potential observed. Acutely dissociated cells from a series of 14 GBMs were fractionated into 
four groups: (1) CD1441/CD1332, (2) CD1441/CD1331 (double positive, DP), (3) CD1331/
CD1442 and (4) CD1332/CD1442 (double negative, DN) (Fig. 2a). All samples contained the 
four fractions, with the DN being the largest population (Supplementary Table 4). Quantitative 
PCR with reverse transcription (qRT–PCR) analysis for endothelial markers (Supplementary 
Fig. 3a) demonstrated marked enrichment of VEGFR2 and the endothelial progenitor marker 
CD34 in the CD1441/CD1332 and in the DP populations. CD105 was consistently absentinthe 
CD1331 and CD1441 fractions. To define lineage potential further, DP cells were cultured 
for 5 days in endothelial cell medium which resulted in the downregulation of CD144, the 
upregulation of CD105 and CD31 as well co-expression of VEGFR2 and CD34 and labelling 
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Figure 1 | CD1051 endothelial cells in GBM harbour genomic aberrations. a, FACS analysis and quantification of GBM-
derived CD1051 cells shows co- expression of other endothelial cell markers (CD31, VEGFR2) and uptake of DiI-AcLDL(n 
5 3). FITC, fluorescein isothiocyanate; PE, phycoerythrin
b, CD105 immunostaining in GBMs delineates microvessels co-labelling with CD31 and glomeruloid vessels 
surrounded by caldesmon (CALD)-expressing pericytes. c, Functional neovessel formation by GBM-derived 
CD1051 cells in the flank of NOD-SCID mice. Confocal immunofluorescence demonstrates
co-localization of a human mitochondria marker with CD31 and uptake of lectin by the CD1051 vessels in the 
implants. d, Immuno-FISH of CD1051 vessels in GBM specimens (case 76, 78) shows multiple copies of the 
EGFR amplicon (arrows). e, FISH on CD1051 cells sorted from GBMs confirms amplification of EGFR (red) and 
chromosome 7 centromere (Chr7, green) (arrows). Control nuclei, individually contoured, are from normal 
human fibroblasts. Scale bars, 50 mm. Error bars, s.d.
Glioblastoma stem-like cells give rise to tumour endothelium.
4
53|
Figure 2 | GBM-derived 
CD1331 cells include a fraction 
of endothelial progenitors a, 
Representative FACS analysis 
of a GBM specimen with 
fractionation into four cell 
subpopulations based on the 
expression of CD133 and 
vascular E-cadherin (CD144). 
b, Immunofluorescence analysis 
of DP (CD1331/CD1441) 
cells upon differentiation 
demonstrates co-expression of 
endothelial markers and DiI-
AcLDL uptake. c, d, In Matrigel, 
DP cells will exhibit DiI-AcLDL 
uptake and form tubular 
networks comparable to those 
shown by normal endothelial cells, 
as well as areas of thickened walls 
where cells are more proliferative. 
Scale bars, 100 mm in b and d; 
300 mm in c.
Figure 3 | CD1331/CD1442 
cells are multipotential 
and give rise to endothelial 
cells via an endothelial 
progenitor intermediate. a, 
b, Co- cultures of CD1331/
CD1442 cells with tumour 
cells give rise to endothelial 
progenitors that co-express 
CD133 and CD144 (DP) 
as shown and quantified 
by FACS analysis (n 5 3). 
APC, allophycocyanin. 
c, GFP1-derived DP 
cells form intracellular 
vacuolar structures in 
collagen gel, characteristic 
of endothelial cells. d, 
Immunohistochemistry of 
CD1331/CD1442-derived 
endothelial cells (n = 3). e, f, Single cell clonal analysis of GFP-labelled CD1331/CD1442 cells. GFP1 
clones derived from single cells are seeded under neural or endothelial conditions. Normal endothelial 
precursor cultures (EPC) and human dermal fibroblasts (HDF) were used as controls. Under endothelial 
conditions, all cells except HDF express endothelial but not neural markers. Under neural conditions, 
cells from the same GFP/CD1331 clone are positive for GFAP and nestin but not endothelial markers, 
while controls are negative for all markers. Scale bar, 50 mm. Errors are s.d.
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with DiI-AcLDL (Fig. 2b and Supplementary Fig. 3b). When grown in three-dimensional (3D) 
gel cultures, the in vitro DP- derived endothelial cells form vascular networks reminiscent of 
normal endothelium, but also thickened channel walls and areas of confluence more suggestive 
of abnormal tumour vessels (Fig. 2c, d). The primary CD1051 cells also form glomeruloid-like 
structures in 3D gel, with high lectin uptake (Supplementary Fig. 1c). DP-derived CD1051 cells 
were sorted and injected subcutaneously in NOD/SCID mice, giving rise to vascularized plugs 
identical to those obtained from primary CD1051 cells (Supplementary Fig. 1d).
The CD1441/CD1332 cell fraction was often very small but showed a restricted differentiation and 
immunohistochemical profile (Supplementary Fig. 3c, d). When grown in Matrigel, the CD1441/ 
CD1332cells develop tubular, capillary-like structures19 and noglomeruli (Supplementary Fig. 
3e). CD1441/CD1332 cells do not express neural markers orform neurospheres, thus indicating 
amore restricted endothelial precursor cell identity (Supplementary Fig. 3f ). Unsupervised 
clustering of transcriptome data was performed on several data sets including independent 
samples of the four sorted tumour subpopulations, as well as CD1441human embryonic stem-
cell-derived endothelial precursors and bone-marrow-derived CD341 endothelial progenitors 
(Supplementary Fig. 3g). Taken together, these results indicate that GBMs comprise cell fractions 
capable of endothelial cell differentiation.
The identification of genomic aberrations in tumour endothelium and the presence of endothelial 
progenitors within the CD1331 putative CSC fraction in GBMs, led us to postulate that DP cells 
may represent the neoplastic origin of tumour endothelium and could derive from the CD1331 
CSC fraction. CD1331/CD1442 cells were then labelled with EFa-1::GFP (elongation factor 
a1–green fluorescent protein) lentiviral vectors, triple sorted, and GFP1/CD1331/CD1442 cells 
were cocultured in the presence of tumour cells. On day 5, FACS analysis demonstrated the 
emergence of a GFP1-DP population (Fig. 3a, b). When placed in collagen cultures, the GFP1-
DP cells had intracellular vacuoles suggestive of early lumen formation by endothelial tubes20 
(Fig. 3c), and differentiation into cells that express CD105 and CD31 and exhibit DiI-AcLDL 
uptake (Fig. 3d and Supplementary Fig. 4a). Importantly, co-culture with tumour cells is essential 
for the emergence of DP cells (Fig. 3a, b). Our data confirm that the DP endothelial progenitors 
within GBM can arise from the CD1331 cell population and are capable of differentiating into 
endothelial cells of tumour origin. Of note, the tumour cells used in these co-culture experiments 
originate from tumours with different genetic backgrounds and transcriptomal subclasses 
(Supplementary Tables 2 and 3).
Recent data support a close interaction21 or a lineage relationship22 between endothelial cells and 
neural stem cells. We next explored whether endothelial differentiation of CD1331/CD1442 can 
be further promoted by extrinsic signals. To this end, CD1331/CD1442 cells were isolated from 
GBM samples, stably transduced with EFa-1::GFP lentiviral vectors, sorted for GFP1/CD1331/
CD1442 and co-cultured with tumour-derived endothelial cells. GFP-expressing endothelial 
cells were identified at 7–10 days in vitro as demonstrated by co-labelling of GFP with CD105 
and CD31, and also incorporation of DiI-AcLDL. Control experiments using GFP-labelled 
CD1332 cells did not yield any endothelial cells (Supplementary Fig. 4b). The CD1331/CD1442 
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population formed neurospheres and readily differentiated along the three main CNS lineages 
(Supplementary Fig. 4c). Whereas these data are suggestive of the multipotent nature of the 
CD1331/CD1442 cells, they do not rule out the presence of heterogeneous populations within 
the CD1331/CD1442 fraction with distinct differentiation potentials. We thus performed single-
cell clonal studies of CD1331/CD1442 cells as well as normal endothelial cells and fibroblasts 
as controls (Supplementary Fig. 4d). The data demonstrate both endothelial and neural 
differentiation potential within a single-cell derived clone confirming that CD1331/CD1442 
cells are capable of generating tumour cells and tumour-derived endothelium (Fig. 3e, f ). FISH 
for EGFR and chromosome 7 in the clones confirmed the presence of genomic amplifications 
identical to those exhibited by the parent tumour tissue (Supplementary Fig. 4e).
We next tested the fate of the various tumour cell fractions upon transplantation in vivo. CD1331/
CD1442, DP, CD1441/CD1332 and DN cells were injected into the striatum of immunodeficient 
mice. All grafted animals developed tumours with the exception of those that CD1331/CD1442 
gave rise to large, highly infiltrative and hyperproliferative tumours showing strong expression of 
nestin (Fig. 4a). Whereas all xenograft tumours had a comparable volume and proliferation rate, 
the DP-derived tumours showed significantly increased levels of vascularization as demonstrated 
quantitatively (Supplementary Fig. 5a).
Some of the animals were grafted with stably GFP-marked CD1331 cells allowing us to serially 
passage GFP-labelled CD1331/CD1442 cells from the primary xenograft in NOD-SCID mice. 
Secondary tumours formed at similar efficiency and showed comparable cell composition to 
the first passage cells. FACS analysis of GFP labelled xenograft cells demonstrates expression of 
endothelial markers, including CD105 and CD34 (Fig. 4b). After a second passage in vivo, tumours 
were sorted again for GFP1/CD1331/CD1442 cells, which upon culture gave rise to GFP-labelled 
CD311 and CD1051 cells, thus demonstrating maintenance of the multipotential phenotype 
(Fig. 4c). Immunohistochemical analysis, including confocal microscopy, demonstrated tumour 
blood vessels with typical morphology that express human markers. Tumour-bearing animals 
were also injected systemically with lectin, resulting in vessel-specific uptake and colabelling 
with human markers (Fig. 4d, e and Supplementary Fig. 6). Thus, multipotency—including 
differentiation capacity along endothelial lineages—is maintained within the CD1331/CD1442 
population in vivo and upon passaging. However, in the absence of clonal studies in vivo, true 
multipotency of tumour stem-like cells cannot be definitively confirmed.
A more comprehensive and quantitative analysis of genomic aberrations was conducted in order 
to verify the lineage relationship among the different tumour subpopulations. qPCR for the 
EGFR exons as described above6 demonstrates the highest copy number within the CD1331/
CD1442 population followed by the endothelial progenitors (DP) and the CD1051 cells 
(Supplementary Fig. 5b). Interestingly, the CD311 cells and the CD1441/CD1332 progenitors 
showed lower levels of amplification, indicating that they may include a significant proportion 
of genotypically normal cells. We propose that these cells largely represent normal endothelium 
and circulating endothelial progenitors, respectively. This is compatible with the more restricted 
endothelial fate demonstrated by the CD1441/CD1332 cells as shown above (Supplementary 
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Figure 4 | Cancer stem-like cells and endothelial progenitors give rise to tumour and endothelial cells in vivo. a, 
Representative magnetic resonance imaging (MRI) images from mice that received injection of DN, CD1331/ 
CD1442 or DP cells from primary GBM specimens. T2 sequences demonstrate infiltrative tumours except in the 
DN group. Tumours were hypercellular on haematoxylin and eosin (H&E), showed high proliferation rates (Ki67) 
and nestin expression. Immunostaining for human-specific CD31 demonstrates the presence of vessels of human 
origin within the tumours. NA, human nuclear antigen. b, FACS plots (left) and quantitative analysis (right) for 
endothelial marker expression in xenograft tumours (GFP1/CD1331/CD1442 cells) and controls (DN). (n 5 3, 
s.d.). 7-AAD, 7-aminoactinomycin. FL-1 and 2, fluorescent channels 1 and 2; mIgG, mouse immunoglobulin 
G. c, Xenograft derived GFP1/CD1331/CD1442 cells express endothelial markers upon in vitro differentiation 
(arrows). d, Uptake of systemic lectin in tumour xenografts demonstrates blood vessels that co-label with human 
endothelial markers (CD31 and CD105). e, Confocal microscopy of xenograft microvasculature. Scale bars, 100 
mm in a; 50 mm in c; 140 mm in d; 10 mm in e.
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Fig. 3c, e, f ). Quantitative FISH studies for copy number of EGFR and chromosome 7 per 
cell were performed on CD1331/CD1442, DP and CD1051 cells and revealed a substantial 
proportion of cells bearing the neoplastic aberrations in each population, ranging from 47.3% 
to 71.7% (Supplementary Fig. 5c). To address genomic alterations in tumour cells in a more 
unbiased manner we performed array comparative genomic hybridization (CGH) on the 
fractionated populations (Supplementary Fig. 7). The CGH data showed similar patterns of 
genomic aberrations in tumour cells as well as the endothelium and its progenitors, at variable 
amplitudes and across different regions, thus demonstrating a similar paradigm even in tumours 
that do not exhibit EGFR gain. We performed transcriptome analyses on a set of 18 tumours 
used in this study and found a random distribution of commonly described genotypes as well as 
representation of all TCGA-defined transcriptomal classes (Supplementary Table 3). Finally, we 
performed metaphase spreads on purified cell fractions of CD1331/CD1442, DP and CD1051 
following short-term culture. The majority of the cells had a highly abnormal but neardiploid 
karyotype, indicating that nuclear fusion is a very unlikely explanation for the lineage transition 
from cancer cell to endothelial progenitor or mature cell (Supplementary Fig. 5d). Vascular 
mimicry has been described in melanoma23 and other tumours24; aneuploidy was also shown in 
renal cell cancer endothelium, but not matched to parent tumour cells25.
We investigated the impactof DAPT (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine 
t-butyl ester), a γ-secretase inhibitor that effectively inhibits Notch signalling8, and bevacizumab, 
a VEGFA- binding antibody7 currently in clinical use, on the differentiation of CD1331/CD1442 
to DP and then to CD1051 cells. Exposure to bevacizumab did not have an impact on the ability 
of CD1331/ CD1442 cells to differentiate into endothelial progenitors, yet it blocked further 
maturation from DP into CD1051 endothelial cells. In contrast, γ-secretase inhibition resulted 
in significant suppression of the transition from CD1331/CD1442 to DP, butdid not affect 
maturation to CD1051 cells. To demonstrate the specific roles of the Notch and VEGF pathways, 
we performed knockdown studies targeting the NOTCH1 and VEGFR2 receptors. The gene 
silencing data further supported the results of the inhibitor studies (Supplementary Figs 8b and 
9). Gene expression analysis shows significant upregulation of NOTCH1/2 and VEGFR1/2 in 
the CD1331/CD1442 and DP groups, respectively (Supplementary Fig. 8). These preliminary 
studies offer a novel perspective of the roles of the VEGF and Notch pathways in glioma biology, 
although the functional consequences of VEGF or Notch blockade remain to be determined.
Despite some promise, bevacizumab therapy is often interrupted by GBM progression 
characterized by a decrease in abnormal vascularity and significant invasive tumour behaviour26. 
Based on the paradigm presented here (Supplementary Fig. 9a), bevacizumab failure could be 
conceivably due to the disruption of the dynamic relationships between the tumour fractions.
In summary, our data demonstrate that a subpopulation of cells within GBM can give rise to 
endothelial cells via a bipotential progenitor intermediate, and that the CD1331 cancer stem-
cell-like fraction includes a population of endothelial progenitors. An in-depth understanding 
of the lineage relationship between tumour cells and endothelial progeny should provide new 
insights into CSC biology and tumour self-renewal. Given the strong correlation of tumour 
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grade and neoplastic vasculature inhuman gliomas, agents that could block endothelial transition 
of tumour cells may provide a novel therapeutic strategy for this currently intractable disease.
Methods summary
All experiments were conducted on freshly obtained surgical specimens of glioblastoma tumour; 
a neuropathologist confirmed the diagnosis on frozen section before tissue acquisition. Tumours 
were newly diagnosed or recurrent. A total of 78 tumours were used in the study. Cell fractions 
were sorted using standard methods at our FACS facility; in vitro experiments were conducted 
on shortpassage cultures (maximum of five passages) if needed. A total of 34 xenografts were 
obtained in immunodeficient mice following intrastriatal implantation of cell populations as 
indicated in the Methods. A lentiviral vector expressing GFP under a PGK promoter (gift from 
M. Sadelain) was used for cell labelling and sorting. Cytogenetic analyses were conducted using 
standard methods at the Cytogenetics Core facility at Sloan Kettering Cancer Center. Knockdown 
experiments were performed using lentiviral vectors expressing shRNA for NOTCH1 or VEGFR2 
(Santa Cruz). All experiments were carried out in triplicates or greater. Data are expressed as 
mean ±s.d. P values were determined following two-tailed student’s t-test. A P value of <0.05 
was considered significant. Tissues were obtained after patients’ written consent under a protocol 
approved by the institution’s Institutional Review Board.
Full Methods and any associated references are available in the online version of the paper at 
www.nature.com/nature.
Received 10 May; accepted 1 November 2010.
Published online 21 November; corrected 9 December 2010 (see full-text HTML version for 
details).
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Methods
Tissue processing. Surgical specimens were collected from the surgical suite at Memorial Sloan 
Kettering Cancer Center, following diagnostic confirmation by a neuropathologist. Tissues 
were obtained after patients’ written consent under a protocol approved by the institution’s 
Institutional Review Board. Tumours were cut mechanically first (McIlwain Tissue Chopper) 
then dissociated into single cells with Liberase Blendzyme 1 (Roche) as described previously27.
Single cells were blocked with human FcR (1:20, Miltenyi Biotec) at 4 uC for 20 min before 
incubation with primary antibodies for 30 min. Cells from xenografts were further blocked 
with 2,4-G2 (1:100; Santa Cruz Biotechnology) before incubation with antibodies. Cells 
were incubated with primary antibodies, washed and reincubated with appropriate secondary 
antibodies and resuspended in FACS buffer27 (containing 1× Ca21/Mg21-free HBSS 
(Invitrogen), 10 mM of HEPES, 0.156% of glucose and 0.5% of low endotoxin BSA fraction V, 
all from Sigma (Sigma-Aldrich), at a pH of 7.2) with 1 mg ml21 7-aminoactinomycin D (7-AAD, 
BD Pharmingen) before analysis. Mouse IgG1 or secondary antibody alone served as control 
for unspecific binding. Samples were analysed on a FACS Aria flow cytometer with CellQuest 
software (BD Biosciences) and data were analysed using FlowJo software (Tree star). A minimum 
of 10,000 events were counted and cell surface expression was analysed in 7-AAD-negative 
live cells. Antibodies used include: phycoerythrinor allophycocyanin-conjugated anti-CD133 
(1:20, Miltenyi Biotec); FITC-conjugated anti-CD144 (1:20, Abcam), anti-CD105 (1:20, BD 
Biosciences) and anti-CD31 (1:20, BD Biosciences); mouse anti-human CD31 (1: 40; BD 
Biosciences), mouse anti-human CD105 (1:40; Dako), mouse anti-human VEGFR2 (1:40; 
Abcam), mouse anti-human CD34 (1:20; Abcam), mouse anti-human CD144 (1:20; Abcam); 
mouse anti-human CD133 antibodies (AC141 and AC133 epitopes (1:20 each), Miltenyi). 
FITC-conjugated lectin and tetramethyl rhodamine isothiocyanate (TRITC)-conjugated lectins 
were purchased from Vector and Sigma separately.
DNA and RNA preparation. FACS-sorted cell populations from 21 glioblastoma patients were 
used to extract total RNA using an Absolutely RNA Nanoprep kit (Stratagene) or an RNeasy 
Kit (Qiagen). All RNA samples were pre-treated with DNase. Sorted cell populations from eight 
glioblastoma patients were used to isolate genomic DNA using the Picopure DNA extraction kit 
(Molecular Devices), followed by phenol (Invitrogen) extraction.
In vivo studies. Adult female NOD/SCID or male NOD/SCID gamma (NSG) mouse (Jackson 
Laboratory) were anaesthetized with ketamine/xylazine (Hospira) and placed in a stereotaxic 
frame (Stoelting Company). Freshly sorted cells were injected into the right striatum immediately 
after sorting at the following coordinates (relative to bregma): AP = +0.5, ML = –2, and DV = 
–2.7. Animals received 10,000 cells each of CD1331/CD1442, CD1332/CD1441 or DP. NSG 
mice received 500 cells each of CD1331/CD1442 or DP. DN cells were used in three separate 
doses (10,000, 50,000 and 100,000 cells). Animals were killed upon exhibiting symptoms. Some 
animals received FITC-conjugated lectin by retroorbital injection before killing. Total animals 
grafted n = 40.
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The gel implantation assay was modified from ref. 11. Briefly, GBM- or DP- derived CD1051 
(106 or 2 × 106 per ml) were resuspended in Collagen IV (Chemicon). GBM- or DP-derived cell-
gel suspension (500 ml) was injected sub- cutaneously below the xiphoid in four or three mice 
separately. Some animals received TRITC-conjugated lectin by tail vein injection before killing. 
After transplantation (21 days) the implants were retrieved, fixed overnight in 4% (v/v) buffered 
formalin at 4 uC, embedded in Optimal Cutting Temperature Compound (O.C.T. compound, 
Sakura Finetek) and sectioned on a freezing cryostat (Leica) for histological examination. Animals 
were housed and cared for in accordance with the National Institutes of Health (NIH) guidelines 
for animal welfare and all animal experiments were performed in accordance with protocols 
approved by our Institutional Animal Care and Use Committee (IACUC).
Animal imaging. In vivo magnetic resonance imaging was performed on a Bruker Biospec 
4.7-Tesla 40-cm horizontal bore magnet. The system is equipped with a 200 mT m21 gradient 
system. Examinations were conducted using a 72-mm birdcage resonator for excitation, and 
detection was achieved using a 3 cm surface coil. T2- weighted spin echo images were acquired 
consecutively using a rapid-acquisition relaxation enhanced sequence (RARE). Animals were 
anesthetized with 2% isoflurane in N2/O2 mixture.
Immunofluorescence. Primary antibodies were chicken anti-GFP (1:1,000; Chemicon), mouse 
anti-human CD31 (1:400; Abcam); mouse anti-human CD34 (1:400; Abcam), mouse anti-
human CD105 (1:400; Dako); mouse anti-human vWF (1:100; Dako); mouse anti-human 
VEGFR2 (1:200; Abcam); mouse anti-human Ki67 (1:400; Dako); mouse anti-human NCAM 
(1:150; Santa cruz Biotechnology), mouse anti-human mitochondria (1:200; Chemicon), mouse 
anti-human nestin (1:400; Millipore), mouse anti-human nuclear antigen (1:500; Chemicon), 
rabbit anti-human GFAP (1:1,000; Chemicon), mouse anti-human Tuj1 (1:500; Covance), 
mouse anti-O4 (1:200; Chemicon), rabbit anti-human caldesmon (1:400; Novus Biology). The 
following secondary antibodies were used: Alexa Fluor 488-conjugated goat anti-chicken or 
mouse or rabbit (1:1,000), Alexa Fluor 555-conjugated goat anti-mouse or rabbit (1:1,000), Alexa 
Fluor 555-conjugated goat anti-mouse IgM (1:500), all from Molecular Probes (Invitrogen).
Cell culture and clonal assays. GFP labelling was obtained by incubation with a PGK-GFP 
lentiviral vector (gift from M. Sadelain). For sphere cultures, freshly sorted CD133 /CD144, 
DP and CD133 /CD144 cells were cultured under clonal conditions (1,000 cells per cm2 or 
5 cells per µl) in low-adherence plates (Corning) and maintained in serum free-Neurobasal 
medium supplemented with N2 (Invitrogen), 2 mM L-glutamine, 20 ng ml–1 recombinant 
human epidermal growth factor, and 10 ng ml21 recombinant human fibroblast growth factor 2 
(all from Invitrogen). Neurospheres were reseeded every 5 days after dissociation with Accutase 
(Innovative Cell Technologies). For neural differentiation, CD1331/ CD1442 cells were cultured 
in laminin coated plates (BD Biosciences) using NeuroCult NS-A Differentiation Kit (human) 
(Stem Cell Technologies).
For endothelial progenitor cells, freshly sorted DP or CD1441/CD1332 cells were seeded on 
human fibronectin-coated plates (BD Biosciences) at a density of 105 ml21 with endo-cult liquid 
medium Kit (Stem Cell Technologies) for propagation. DP, CD1441/CD1332 or CD1331/
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CD1442-derived DP cells were grown to 75% confluence and switched to M199 medium 
(Invitrogen) for quantification of endothelial differentiation as described previously19. GBM-
derived CD1051 cells were grown in M199 medium19 for 2 days before FACS analysis. The 
functional assay for endothelial cells was performed by incubation of cells with 10 mg ml21 of 
DiI-labelled acetylated low density lipoproteins (DiI-AcLDL) (Molecular Probes, Invitrogen) 
for 4 h.
For DP inductionculture, GFP-labelled CD1331/CD1442wereco-culturedwith tumour cells 
at a 20:1 ratio in N2 medium. The CD1331/CD1442-derived DP cells were sorted by FACS 
after 5 days for further characterization. A minimum of 100 cells were counted in triplicate 
assays. They were cultured in three-dimensional collagen gel20. For differentiation of CD1331/
CD1442 to endothelial cells, tumour endothelial cells and GFP labelled CD1331/CD1442 cells 
or control cells were resuspended in endo-cult medium and grown on fibronectin coated plates 
for 7 days at a ratio of 100:1. Single cell clonal assays were performed by seeding freshly sorted 
single GFP-labelled cells on multi-well plates. Wells containing single green cells were identified 
and monitored until clone formation is established. Single-cell-derived clones were further sub-
cloned and propagated twice, dissociated and seeded under neural and endothelial differentiation 
conditions as described above. Human umbilical cord-derived CD1331 endothelial precursor cells 
(Biochain) or humandermal fibroblasts (Cell Applications) were maintained as per manufacturer 
instructions and used as control in clonal analysis.
Inhibitor studies. For drug treatment assays, cells were cultured in DP induction medium or 
endothelial differentiation medium containing 5 mM of the γ-secretase inhibitor DAPT (N-[N-
(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester, Sigma-Aldrich) or 1 mg ml21 of 
bevacizumab (Genentech). Treated cells were analysed by FACS analysis after 48 h incubation. 
VEGF was measured in the culture medium with a human VEGF ELISA Kit (Invitrogen) 
following the manufacturer directions.
Knockdown studies. GBM-derived fresh DP and GFP-CD133sp cells were infected 
with shRNA virus targeting VEGFR2 or NOTCH1 or a control virus (all from Santa Cruz 
Biotechnology). NOTCH1 shRNA lentiviral vector mix contains three target-specific constructs: 
CACCAGTTTGAATGGTCAATTCAA GAGATTGACCATTCAAACTGGTGTTTTT; 
CCCATGGTACCAATCATGA TTCAAGAGATCATGATTGGTACCATGGGTTTTT; 
CCATGGTACCAATC ATGAATTCAAGAGATTCATGATTGGTACCATGGTTTTT. 
VEGFR2 shRNA lentiviral vector mix contains three target-specific constructs: 
ACTGTGGTGATT CCATGTCTTCAAGAGAGACATGGAATCACCACAGTTTTTT; 
ACTTGTAA ACCGAGACCTATTCAAGAGATAGGTCTCGGTTTACAAGTTTTTT; 
CACC TGTTTGCAAGAACTTTTCAAGAGAAAGTTCTTGCAAACAGGTGTTTTT.
The infected cells were selected with 2–4 mg ml21 puromycin (Santa Cruz Biotechnology) and 
used for FACS analysis and/or collected for RT–PCR as described above after 5 days in selection.
In vitro angiogenesis assay. Intracellular vacuole formation was evaluated by culturing CD1331/
CD1442-derived DP cells in three-dimensional collagen gel as described in ref. 20. Tubular 
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network formation was assessed by culture in growth factor reduced Matrigel assay Kit (BD 
Biosciences) following the protocol from ref. 19.
Cytogenetic analyses and genomic PCR. Fluorescence in situ hybridization was performed 
using BAC clone RP11-339F13 and PAC clone RP5-1091E12 spanning the EGFR locus in 
7p11, both labelled with Red-dUTP, together with a chromosome 7 centromere repeat DNA 
probe labelled with Green-dUTP targeted at the centromeric region of chromosome 7 (7p11.1–
7q11.1 D7Z1 alpha satellite region). FISH was performed on sorted cells post cytospin on glass 
slides. A minimum of 100 cells in interphase were analysed. Human dermal fibroblasts (HDF) 
served as normal control. The false positive rates for FISH probes was determined as 1% (s.d. 
5 1.3) and the cut-off level for the diagnosis of amplification was set at 5% (.3s.d.) (n 5 3, total 
counted 2,000 control cells).
FISH on tumour sections, as reported in Supplementary Tables 1b and 2, was performed 
independently by the Clinical Cytogenetics Facility at Memorial Sloan Kettering Cancer Center, 
as part of a now routine molecular diagnostic test. The probe used is the 7p12 LSI EGFR and 
the 7p11.1–7q11.1 CEP (D7Z1 alpha satellite) dual colour probe, purchased from Abbott 
Molecular.
Fluorescence immunophenotyping and interphase cytogenetics, a technique combining 
immunohistochemistry for CD105 and FISH for EGFR, was carried out on 10-mm thick tissue 
sections. Normal human brain cerebral-cortex sections (Biochain) were used as controls.
In a copy number quantification reaction by real-time PCR, EGFR primers were designed based 
on published data6,28,29,30. Genomic DNA (10 ng) from sorted cells or normalhumanbrainwas 
usedastemplate to examine thecopy numberof exons 4, 9, 11 in the EGFR gene; GAPDH was 
used as reference gene. Each replicate was normalized to GAPDH to obtain a DCt, and then an 
average DCt value for each sample (from the three replicates) was calculated. All samples were 
then normalized to thecalibrator sample (normal humanbrain) to determine DDCt. Relative 
quantity (RQ) is 2DDCt, and copy number is 2 3 RQ. The EGFR copy number in each population 
was defined by the average of copy number from three exons. Error bars indicate the range of the 
data from the three exons in each of the three samples.
Karyotype analysis was performed on metaphase spread of FACS-purified cell subpopulations 
that were in culture for 3 days. The cultures were treated with Colcemid (0.1 mg ml21) for 1.5 h 
before in situ metaphase preparation according to standard cytogenetics procedures.
CGH studies. Comparative genomic hybridization (CGH) assay was performed by hybridizing 
genomic DNA from sorted cells with 44K human genome CGH arrays, and frozen banked whole 
tumour on 244K and 1M human genome CGH arrays (all commercial arrays from Agilent). 
DNA from sorted cells was prepared as described above. DNA extraction, purification, labelling 
and hybridization were performed at Sloan Kettering Cancer Center’s Genomics Core Facility 
according to the manufacturer’s instructions. Log2 ratios were normalized by Lowess against 
probe intensity and mean %GC of the genomic region mapped to by the probe. Segmentation 
of normalized log2 ratios was by Circular Binary Segmentation (CBS, R package DNAcopy).
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A separate method was used to investigate whether an amplicon identified by CBS in one cell 
fraction might be present in a minor subpopulation in other cell fraction at a level not detected 
by CBS. A region of interest (ROI) is defined by the boundaries of the amplicon detected by 
CBS. Then this region is investigated in the CGH profiles of the other cell fractions as follows: 
the log2 ratios of the N probes under the ROI (within amplicon boundaries) are compared to 
log2 ratios of all the other probes in the entire chromosome by Student’s t-test (one-tailed). 
The observed t-score is then compared to the distribution of t-scores obtained by equivalently 
testing all other sets of N neighbouring probes in the chromosome. The ROI is considered to 
be significantly gained if the observed t-score is seen or exceeded in less than 0.1% of all other 
chromosomal regions.
Expression microarray studies of whole tumours. Gene expression profiling was performed for 
a subset of 16 tumours for which additional frozen material was available using exon expression 
arrays (Human Exon 1.0, Affymetrix). RNA was extracted, labelled and hybridized at Sloan 
Kettering Cancer Center’s Genomics Core Facility according to the manufacturer’s instructions. 
Data was normalized in a cohort of 80 gliomas using Aroma.affymetrix (R package aroma.
affymetrix). Expression was derived for RefSeq transcripts, and multiple transcripts for the same 
gene were distilled to a single gene expression value by median.
Transcriptomal class assignment was based on the nearest centroid of the four transcriptomal 
classes reported in ref. 13, using the subset of 840 signature genes described by this study 
(Supplementary Table 6; http://tcga-data.nci.nih.gov/docs/ publications/gbm_exp/). Distances 
to centroids were defined using Pearson correlation and class assignments made by the largest 
correlation value. If the largest correlation was ,0.2, the sample was labelled ‘indeterminate’. 
Correlations and class assignments are given in Supplementary Table 6.
Microscopic analysis. Sections were examined with confocal laser scanning microscopy (Leica 
Microsystems; Carl Zeiss MicroImaging). The data was analysed with Velocity or LSM5 (Carl 
Zeiss MicroImaging) software.
Tumour microvessel density (MVD) was assessed by quantification of the numbers of CD311 
tumour vessels in pixels using MetaMorph (Molecular Devices) image analysis software using 
unbiased sampling.
Gene expression analysis and quantitative real-time PCR for sorted cell populations. Total 
RNA of four subpopulations from two specimens were hybridized with human U133-plus2 array 
at Sloan Kettering Cancer Center’s Genomics Core Facility and according to the manufacturer’s 
instructions. Reference databases, including one set of CD341 human haematopoietic progenitor 
cells (GSM476781) and two independent sets of human embryonic stem cell-derived endothelial 
progenitors (GSM492830 and GSM492828) were downloaded from Gene Expression Omnibus 
database. The array data are analysed by Partek software.
The data from 11 samples were normalized by RMA algorithms and the tumour samples then 
assigned in four groups based on the expression of membrane markers CD133 and CD144. The 
gene list is created by ANOVA with unadjusted P value less than 0.05 and then used as input for 
unsupervised hierarchical clustering by using Euclidian similarity metric.
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For RT–PCR, total RNA (100–300 ng) was reverse-transcribed using random- primer and 
superscript III (Invitrogen) according to the manufacturer’s instructions. Quantitative real-time 
PCR was performed with an Applied Biosystems Prism 7900HT sequence Detection System 
using SYBR Green PCR Master Mix (Applied Biosystems).
Primers: CD34 (F: TCTGATCTCCATGGCTTCCT; R: ACTGAGGCAACAG CTCAACC), 
CD144 (F: TCGTCATGGACCGAGGTT; R: TCTACAATCCCTT GCAGTGTGA), 
VEGFR2 (F: GCAGGGGACAGAGGGACTTG; R: GAGGCC ATCGCTGCACTCA), 
CD31 (F: TTCCTGACAGTGTCTTGAGTGG; R: GCT AGGCGTGGTTCTCATCT), 
CD133 (F: TCTGGGTCTACAAGGACTTTCC; R: GCCCGCCTGAGTCACTAC), ACTIN 
(F: GCCCGCCTGAGTCACTAC; R: GGAATCCTTCTGACCCATGC), VEGFR1 (F: 
TCTCACATCGACAAACCA ATACA; R: GGTAGCAGTACAATTGAGGACAAGA), VEGF 
(F: CTACCTCC ACCATGCCAAGT; R: CCACTTCGTGATGATTCTGC).
Human angiogenesis PCR arrays (SABiosciences) were used to examine the expression profiles of 
angiogenic genes in sorted cell populations. Heat Map construction and analysis of qPCR data 
was conducted according to ref. 31.
27. Panchision, D. M. et al. Optimized flow cytometric analysis of central nervous system tissue reveals 
novel functional relationships among cells expressing CD133, CD15, and CD24. Stem Cells 25, 
1560–1570 (2007).
28. Franco-Hernandez, C. et al. Gene dosage and mutational analyses of EGFR in oligodendrogliomas. 
Int. J. Oncol. 30, 209–215 (2007).
29. Mellinghoff, I. K. et al. Molecular Determinants of the response of glioblastomas to EGFR kinase 
inhibitors. N. Engl. J. Med. 353, 2012–2024 (2005).
30. Brennan, C. et al. Glioblastoma subclasses can be defined by activity among signal transduction 
pathways and associated genomic alterations. PLoS ONE 4, e7752 (2009).
31. Guo, P. et al. Dual nature of the adaptive immune system in lampreys. Nature 459, 796–801 (2009).
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Glioblastoma multiforme (GBM) is one of the most aggressive brain tumors. 
GBM cell lines used in laboratory studies are frequently passaged in various culture 
media at high proliferation rates, resulting in significant genetic and molecular 
alterations. Thus, data obtained in cell lines are often inapplicable to patient 
tumors. Furthermore, recent studies suggest that there is a stem cell–like hierarchy 
among GBM cell populations and a crucial role for tumor vasculature in stem 
cells, as well as tumor growth, which cannot be reproduced in cell line cultures. 
Our laboratory has developed a novel three-dimensional (3D) organotypic 
“explant” system of surgical GBM specimens that preserves tumor cells in their 
original milieu, as well as the cytoarchitecture of the tumor stroma. Our previous 
study on the role of Notch inhibition has demonstrated a definitive effect on the 
tumor endothelium that could only be highlighted by this system. In this unit, we 
describe a detailed protocol for preparing GBM explants, and discuss strengths, as 
well as limitations of the explant system as an in vitro 3D model of GBM. Curr. 
Protoc. Stem Cell Biol. 19:3.5.1-3.5.9. © 2011 by John Wiley & Sons, Inc.
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Introduction
This unit describes a recently developed protocol for preparing organotypic cultures of 
glioblastoma multiforme (GBM) to explore basic glioma biology, as well as to utilize in 
preclinical screens for therapeutic agents. In this model, tumor tissue obtained directly 
from the operation room is dissected into small pieces or “explants” and are maintained in 
an air-liquid interface either on Millicell (Millipore) or Transwell (Corning) semiporous 
membranes (Figs. 3.5.1 and 3.5.2A). This model was originally designed for the study of 
normal physiological properties in central nervous tissue slices (Stoppini et al., 1991; 
Ga¨hwiler et al., 1997). For the GBM explant culture, we use chemically defined media 
without additional growth factors or sera (Hovinga et al., 2010), to avoid selective growth of 
stem/progenitor cell population or their differentiation. The GBM explants are maintained for 
a relatively short period (up to three weeks) before they are harvested for downstream analyses 
including immunohistochemistry, flow cytometry, and neurosphere assay.
This unit begins with a method for establishing a GBM explant culture (Basic Protocol 1), 
followed by a protocol for dissociating the cells (Basic Protocol 2) to perform flow cytometry 
analysis and neurosphere assay.
Current Protocols in Stem Cell Biology 3.5.1-3.5.9
Published online December 2011 in Wiley Online Library (wileyonlinelibrary.com). DOI: 
10.1002/9780470151808.sc0305s19
Copyright ©2011 John Wiley & Sons, Inc.
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Figure 3.5.1 A diagrammatic representation of the organotypic explant culture system and the neurosphere (or 
“gliomasphere”) culture system of glioblastoma multiforme (GBM).
NOTE: The following procedures are performed in a Class II biological hazard flow hood or a laminar-flow hood.
NOTE: All solutions and equipment coming into contact with live tissue and cells must be sterile, and proper 
aseptic technique should be used accordingly.
NOTE: All incubations are performed in a humidified 37°C, 5% CO2 incubator unless otherwise specified.
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Figure 3.5.2 (A) Six explants from a GBM cultured on a Millicell insert placed on a 35-mm culture dish. (B) 
Heterogenic tissues from a single GBM tumor on a 100-mm culture dish. Upper row from the left: gray normal-
like tissue, orange normal-like tissue, creamy-white spongy (necrotic) tissue, and hemorrhagic tissue; lower row: 
soft and gelatinous tissue. (C-E) Hematoxylin and eosin staining of the gelatinous tissue (C), spongy tissue (D), 
and normal-like tissue (E). Scale bars: 100 µm. (F) ATP-based viability assay was performed on GBM explants 
cultured for 10 days in vitro. Data represents mean ± standard error (n = 3). (G) 3D reconstruction of confocal 
immunofluorescence images of CD31 (red) and nuclei (blue) of an explant (adapted from Hovinga et al., 2010). 
Grid: 50 µm.
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Organotypic GBM explant culture
Laboratory studies of glioma biology have long relied upon the use of dissociated glioma cell 
lines, which are evaluated in isolation from the tumor microenvironment, and are extensively 
passaged in the presence of serum. In view of the growing awareness of the role of the tumor 
stroma (specifically, the vascular niche) to the integrity of the tumor stem cell pool (Joyce, 2005; 
Calabrese et al., 2007), we have optimized the organotypic explant culture model of GBM, in 
which the original cytoarchitecture of the tumor is maintained. The interface culture method (Fig. 
3.5.2A) offers advantages in experiments that require sectioning of the tissue for morphological 
studies, or for biochemical studies that require larger amounts of tissue (Ga¨hwiler et al., 1997). 
The opened interface of the culture also allows, at all stages of culturing, the tridimensional 
observation throughout the thickness of the explants, and has been used for transplantation studies 
investigating glioma cell migration in normal brain tissue (Jung et al., 2002). We have established 
correlations between the explants and their corresponding parent tumors, whereby histology, 
vascularity, and proliferation rates were shown to be similar (Hovinga et al., 2010). Explants can 
be used to analyze the impact of treatments, such as small molecule drugs and irradiation on 
tumor cells, as well as endothelial cells (Hovinga et al., 2010). Media can be used for ELISA or 
other studies to analyze cytokines and growth factors secreted by the tumor. Explants can also 
be dissociated into single-cell suspensions for flow cytometry analyses and neurosphere assays.
Materials
GBM (tumor) specimen on ice
Phosphate-buffered saline, calciumand magnesium-free (CMF-PBS; Invitrogen, cat. no. 21600)
Penicillin/streptomycin
Red blood cell (RBC) lysis buffer (eBioscience) Ice
Fibronectin (see recipe)
Explant culture medium (N2 medium; see recipe)
35- and 100-mm culture dishes Stereoscopic dissecting microscope
Leica KL 1500 LCD (150-watt cold light source) 27-G ½-in. needles
1-ml syringes
Millicell inserts (Millipore) Scalpel no.10 (BD)
Prepare the GBM explants
1. Place the tumor specimen in a 100-mm culture dish, and rinse the tumor with ice-cold 
CMF-PBS containing a high concentration of penicillin/streptomycin (3×).
 The tumor specimen should be obtained as soon as possible from the operating room. If a 
waiting period is unavoidable, the specimen should be placed in a sterile container on ice.
2. Treat the tumor with RBC lysis buffer in the 100-mm culture dish to remove excess 
red blood cells, and then rinse twice with ice-cold CMF-PBS containing penicillin/
streptomycin (3×).
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3. Place the tumor under a dissecting microscope using a cold light source to illuminate the 
tumor. Carefully remove necrotic tissue and large vessels using two 27-G needles attached 
to 1-ml syringes (bend the needle with the bevel facing you). Transfer the viable tissue into 
a new 100-mm culture dish, and place the dish on ice. Add 3 ml of ice-cold CMF-PBS to 
avoid drying of the tissue.
 A relatively small amount of tissue is required to prepare explant cultures ( 2 mm3 per explant). 
Tumors with extensive necrosis will yield less viable explants. With some experience, one learns 
to recognize areas of necrosis (friable avascular tissue) prior to explant preparation.
4. In a laminar flow hood, place Millicell inserts into 35-mm dishes and wet each membrane 
with 50 µl of 1 µg/ml fibronectin in CMF-PBS. Then add 1 ml of explant culture medium 
(without added growth factor or sera) underneath the membrane.
5. Under a cold light source, carefully cut the tumor tissue into small explants ( 2 mm3) 
using a pair of scalpels, and place up to six explants per membrane insert. Add 10 µl of 
medium over each explant to keep it moist but not “flooded” in solution.
 Significant tissue heterogeneity is expected. Care must be taken to avoid bias when grouping 
the explants for each experimental condition (see Critical Parameters and Troubleshooting). We 
try to avoid bias by equally distributing explants originating from adjacent tumor regions into 
all treatment groups, and by preparing a sufficient number of explants (nine to fifteen explants) 
from randomly selected parts within the tumor for each treatment groups.
6.	 Refresh the medium and add 10 µl medium over each explant every other day. Change 
tips for each well to avoid possible cross-contamination.
 Medium collected from the explant culture may be snap-frozen by liquid nitrogen and 
stored at −80°C for analysis of secreted factors.
Preparing single-cell suspension from GBM explants
This protocol describes a method to prepare single-cell suspensions from the cultured GBM 
explants. The cell suspensions may be analyzed by flow cytometry or neurosphere assay to assess 
the presence of “stem-like” cells. Cancer cells with stem-like properties have been characterized 
in various ways including (1) neurosphere formation, (2) multilineage differentiation, (3) active 
proliferation, and (4) tumor formation in vivo. Glioma cells fulfilling these characteristics were 
initially identified as CD133 cells (Singh et al., 2004; Beier et al., 2007), and more recently as 
CD133 /SSEA-1 cells (Son et al., 2009). A marker-independent method to identify glioma-
initiating cells by intrinsic autofluorescence property is also reported (Clement et al., 2010). 
Ability for glioma cells to form neurospheres (or “gliomaspheres”) has been correlated to the 
poor prognosis in patients (Pallini et al., 2008), and a detailed protocol for neurosphere assay is 
described elsewhere (Ferrari et al., 2010).
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Materials
GBM explants cultured on Millicell inserts (see Basic Protocol 1) 
Hank’s balanced salt solution without Ca2+ and Mg2+ (CMF-HBSS)
Liberase I DNase I Glucose Ice
Scalpel no.10 (BD) Forceps
1.5 ml microcentrifuge tubes Microcentrifuge
FACS tubes with cell-strainer cap
1. Finely mince the explants using a pair of scalpels. Cut out the membrane from the 
insert, and transfer the membrane along with the tissue using clean forceps into a 1.5-ml 
microcentrifuge tube containing 1 ml of CMF-HBSS. Mix by inverting the tube several 
times.
2. Shake off the tissue from the membrane, and remove the membrane from the tube using 
forceps.
3. Add 0.4 mg/ml Liberase and 1 µg/ml DNase I, and incubate at 37°C until tissue breakdown 
is evident (approximately 15 to 30 min); mix the tube every 5 min. Occasionally pipet a 
few times to further promote dissociation of cells.
 Breakdown is evident when the solution becomes murky (cells entering suspension).
 Alternatively, Accumax (Innovative Cell Technologies) can be used. In this case, centrifuge the 
tissue and remove 0.5 ml of the dissociation buffer from the tube, and add 0.6 ml of Accumax.
4. Centrifuge 5 min at 1200 rpm, 4C, in a microcentrifuge.
5. Resuspend the tissue in 0.5 ml CMF-HBSS, and pipet up and down 20 times.
6. Filter through the cap of an FACS tube with cell-strainer to remove debris.
7. Transfer the suspension into a microcentrifuge tube and centrifuge for 5 min at 1200 
rpm, 4°C.
8. Wash the cells with 0.5 ml CMF-HBSS containing 0.9 M glucose to remove small debris. 
Centrifuge for 5 min at 1200 rpm, 4°C.
9. Resuspend the cells in 100 to 150 µl HBSS, place the tubes on ice, and proceed to flow 
cytometry or neurosphere assay.
 Typically, 0.5–1 × 106 cells are recovered from five explants.
Reagents and solutions
For culture recipes and steps, use sterile tissue culture–grade water. For other purposes, use deionized, 
distilled water or equivalent in recipes and protocol steps. For suppliers, see SUPPLIERS APPENDIX.
Explant culture medium (N2 medium)
F12/DMEM containing:
1.55 g/liter glucose
2 g/ liter sodium bicarbonate 25 µg/ml insulin
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100 µg/ml human apotransferrin
20 nM progesterone
100 µM putrescine
30 nM sodium selenite
Titrate pH to 7.2 and filtrate
Add penicillin-streptomycin (1 )
Store at 4°C for no longer than two weeks
Fibronectin, 1 mg/ml
5 ml Dulbecco’s phosphate-buffered saline (DPBS; Mediatech, cat. no. 21031 CM) 5 mg BSA
Mix and filtrate
Reconstitute 5 mg fibronectin in the solution above (5 ml of DPBS containing 0.1% BSA)
Divide into 250-µl aliquots Store up to 6 months at −80°C
Dilute at 1:1000 in DPBS before use
Commentary
Background Information
New agents with promising effects in in vitro glioma models have repeatedly failed to be 
efficacious in patients. These in vitro models have long relied upon the use of glioma cell lines, 
which are repeatedly passaged and cultured in various media. Phenotypic characteristics and 
the genetic aberrations found within these cell lines often bear little resemblance to those found 
within the corresponding primary human tumor. For example, 100% of rapidly replicating 
glioma cell lines are undergoing active cell cycle at any given time, while the proliferation indices 
of GBM are generally <20% in situ (Li et al., 2008). This may explain why most drug screens 
have historically identified agents with cytotoxicity against rapidly dividing cells. Recently, the 
concept of tumor stem cells offered a new paradigm of tumor biology, and glioma stem cell 
cultures have been characterized as a more robust model than traditional cancer cell lines (Galli et 
al., 2004; Lee et al., 2006). In this model, freshly dissociated GBM tumor cells are cultured in a 
serum-free medium containing EGF and bFGF, both as nonadherent, multicellular neurospheres 
(or “gliomaspheres”), and as an adherent monolayer in polyornithine/laminincoated dishes. 
These glioma “stem cell” cultures may be closer to the phenotype and genotype of the parental 
tumor, and are perhaps more suitable for chemical and genetic screens especially when grown 
adherently (Pollard et al., 2009), though additional data with clinical correlations are required.
Despite the demonstrated usefulness of these glioma stem cell cultures, the cells are still grown 
in isolation from the tumor microenvironment, including stroma and the vascular niche, which 
has been increasingly gaining attention for its role in supporting the tumor stem cell pool 
(Joyce, 2005; Calabrese et al., 2007). The tumor spheroid system was developed to provide an 
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experimental model of intermediate complexity between the classical two-dimensional culture 
systems and in vivo tumors (Sutherland, 1988). Spheroid cultures are submerged in the medium, 
and are usually grown from established tumor cell lines or, less frequently, from primary tumor 
specimens and may show limited resemblance to the original tumor due to its prolonged passage 
in serum-containing medium. It has been shown, however, that the genomic profile of GBM was 
well preserved in this culture system (De Witt Hamer et al., 2008), perhaps due to its moderate 
proliferation rate. Our approach to the study of GBM in the context of the tumor environment 
was predicated on the preservation of cytoarchitecture and cell population phenotypes, as well as 
a proliferation index comparable to that seen in the original tumor. To this end, we have optimized 
the organotypic explant culture model of GBM. Using this system, we have demonstrated that 
tumor endothelial cells are critical components of the glioblastoma response to Notch inhibition, 
and mediate its effects on tumor proliferation and self-renewal (Hovinga et al., 2010). The explant 
system provides a suitable system to model cell-to-stroma, as well as cell-to-cell communications 
within the tumor and their response to clinical interventions. Specific limitations of the explant 
system should, however, be considered when designing experiments. For example, although the 
vascular structure is preserved in the explants, nutrients, drugs, and immune cells are no longer 
carried through them and thus are no longer functional as blood vessels. Therefore, care must be 
taken when designing experiments involving the blockade of circulation in the blood vessels (i.e., 
anti-angiogenic therapy).
Critical Parameters and Troubleshooting
GBM is recognized for significant heterogeneity at the tissue (Fig. 3.5.2B), cell population, 
molecular, and genetic levels. Some areas are firm while others are soft or gelatinous, and yet others 
are cystic with local hemorrhage. In addition, neoplastic cells infiltrating areas conserving normal 
brain tissue are always present. It should be noted that each of these different tissue types might 
differ in proliferation, cytoarchitecture, and survival under the explant culture condition. From 
our experience, the soft and gelatinous tissues are often densely populated with neoplastic cells 
(Fig. 3.5.2C), in contrast to the firm and spongy tissues, which are almost devoid of cells (Fig. 
3.5.2D). Tissue with high cellularity usually exhibit excellent tissue maintenance and viability 
under the explant culture condition. Importantly, the soft and gelatinous tissue should not be 
confused with the soft normallike brain tissue (Fig. 3.5.2E), which often exhibit low viability 
in culture (Fig. 3.5.2F). In addition to the overt tissue heterogeneity, there are also well known 
regional differences in gene expression, and non-uniform representation of key gene mutations 
and genomic alterations within the same GBM specimen (Inda et al., 2010). Such heterogeneity 
could potentially become the source of significant interexplant variations during downstream 
analyses. Care must therefore be taken to avoid bias in tissue heterogeneity when comparing the 
control versus treated groups of explants. We try to avoid bias by equally distributing explants 
originating from adjacent tumor regions into different treatment groups, and by preparing a 
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sufficient number of explants (nine to fifteen explants per treatment group) from randomly 
selected regions of the tumor.
It is critical to prepare explants at an adequate size to avoid artificial cell death and necrosis 
due to insufficient penetration of nutrient factors and oxygen deprivation. Extensive studies 
in the spheroid culture system have established that for most types of human tumor cells, the 
thickness of sufficient nutrient penetration ranges from 100 to 220 µm (Sutherland, 1988). 
Although the size of the explants (2 mm2) in this protocol largely exceeds such range, we usually 
see an excellent viability throughout the thickness of explant, which may be in part because 
most explants flatten out along the membrane over the course of culture (Ga¨hwiler et al., 
1997; Hovinga et al., 2010). As for penetration of drugs, we have not directly measured levels 
but have demonstrated downregulation of downstream effectors of the Notch pathway upon the 
addition of small molecule Notch inhibitors (Hovinga et al., 2010). We have also successfully 
used toxin-conjugated antibodies that selectively attach to and kill endothelial cells throughout 
the explant thickness (Hovinga et al., 2010). To ensure penetration of macromolecules, such as 
immunoglobulins, however, it may be necessary to make smaller explants (about half the usual 
size) and make small incisions to allow sufficient penetration. We have not experimented with 
other techniques requiring access to individual cells, and thus tissue penetration, such as direct 
viral infection of explant tissue or the use of small RNA molecules.
Anticipated Results
The explant culture system is very robust and, in experienced hands, the likelihood of successfully 
establishing explant cultures for a given tumor exceeds 90%. The explants survived well and 
were kept in culture for up to 3 weeks. The original cytoarchitecture was preserved with strong 
similarities between the parent tumor and its corresponding explant (Hovinga et al., 2010). 
Endothelial hyperplasia and vascular glomeruloid bodies (Fig. 3.5.2C), highly characteristic 
features of GBM, were also preserved in explants (Hovinga et al., 2010). Three-dimensional 
architecture was preserved as seen in the maintenance of a highly branched appearance of the 
capillary network within the explant (Fig. 3.5.2G). Tumor cells in the explant exhibit a high 
proliferation rate as demonstrated by BrdU incorporation and Ki-67 immunostaining (Hovinga 
et al., 2010). For a quantitative analysis, we compared the number of proliferating cells and 
the number of endothelial cells in matched sets of original tumors and corresponding explants 
and observed essentially identical values (Ki-67 of 18.5% and 16.7% and CD105 of 10.1% and 
9.3%, respectively; Hovinga et al., 2010). Immunohistochemistry or FACS analyses for markers, 
such as GFAP, Nestin, CD133, and in vitro uptake of BrdU also shows minimal variability over 
the 5 to 14 days period tested (Hovinga et al., 2010). These data demonstrate minimal changes 
in tumor cell composition, marker expression, and cell proliferation in our in vitro culture system 
over time.
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Time Considerations
Depending on the size of the tumor, 30 to 120 explants can be prepared within 1.5 to 3 hr. For 
preparation of single-cell suspensions from the explants, it should take 1.5 to 2 hr to process 
<10 culture membranes (with five explants per membrane), and 2 to 4 hr to process >10 inserts. 
Counting and plating the cell suspensions for the neurosphere assay will take another 1 to 1.5 hr, 
and another 2 to 3 hr to complete the FACS analysis.
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Glioblastoma multiforme (GBM) is a highly heterogeneous malignant tumor. 
Recent data suggests the presence of a hierarchical organization within the GBM 
cell population that involves cancer cells with stem-like behavior, capable of 
repopulating the tumor and contributing to its resistance to therapy. Tumor stem 
cells are thought to reside within a vascular niche that provides structural and 
functional support. However, most GBM studies involve isolated tumor cells 
grown under various culture conditions. Here, we use a novel three-dimensional 
organotypic ‘‘explant’’ system of surgical GBM specimens that preserves 
cytoarchitecture and tumor stroma along with tumor cells. Notch inhibition in 
explants results in decreased proliferation and self-renewal of tumor cells but is 
also associated with a decrease in endothelial cells. When endothelial cells are 
selectively eliminated from the explants via a toxin conjugate, we also observed 
a decrease in self-renewal of tumor stem cells. These findings support a critical 
role for tumor endothelial cells in GBM stem cell maintenance, mediated at least 
in part by Notch signaling. The explant system further highlighted differences 
in the response to radiation between explants and isolated tumor neurospheres. 
Combination treatment with Notch blockade and radiation resulted in a 
substantial decrease in proliferation and in self-renewal in tumor explants while 
radiation alone was less effective. This data suggests that the Notch pathway plays 
a critical role in linking angiogenesis and cancer stem cell self-renewal and is thus 
a potential therapeutic target. Three-dimensional explant systems provide a novel 
approach for the study of tumor and microenvironment interactions. STEM 
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Introduction
The prognosis for the malignant brain tumor glioblastoma multiforme (GBM) has remained 
poor for decades, with a median survival of about 1 year [1]. In combination with surgery, 
the most effective treatment for GBM is radiation, but its efficacy is limited due to significant 
radiation resistance. A small subpopulation of ‘ stem-like’ cells is now thought to contribute 
to this radioresistant phenotype and lead to repopulation of the tumor after treatment [2–4]. 
Brain tumor stem cells share characteristics with normal neural stem cells, such as neurosphere 
formation, the capacity to differentiate into multiple lineages and possibly interaction with a 
complex stem cell niche that includes endothelial cells [5–7]. In fact normal neural stem cells 
have been proposed as the potential cells of origin of glioblastoma [8, 9].
Notch signaling is an evolutionarily well-conserved pathway that plays a key role in many 
aspects of development such as cell differentiation, proliferation, and apoptotic events, but the 
specific effects are highly context dependent [10, 11]. There are four human Notch receptors 
that consist of an extracellular peptide containing epidermal growth factor (EGF) receptor-
like repeats and a transmembrane peptide. They display both overlapping and distinct tissue 
distributions as well as both redundant and distinct functions [12]. Notch 1 and Notch 2 are the 
most ubiquitously distributed whereas Notch 2 and Notch 4 are more specifically expressed in 
vascular smooth muscle and endothelial cells [13]. Ligand binding via the Jagged or Delta-like 
family of membrane proteins leads to cleavage of the receptor by members of the A Disintegrin 
And Metalloprotease (ADAM) and γ-secretase families of proteases. This results in the release 
of the Notch intracellular domain (NICD), which translocates to the nucleus where it interacts 
with members of the C-Promoter binding factor (CBF1), Suppressor of Hairless, Lag 1 
(Longevity Assurance Gene) (CSL) family and recruits multiple coactivators and corepressors 
leading to activation of target genes as well as NICD degradation. Notch is thought to target the 
transcription of multiple genes, including members of the basic Hes (helix- loop-helix family) 
and Hey (hairy and enhancer of split related with XRPW modif ) [14]. The Notch pathway 
plays a major role in maintenance of the stem cell state in the nervous system [15, 16] and in 
the regulation of angiogenesis in normal development as well as tumors including glioblastoma 
[17–19]. It also interacts closely with the vascular endothelial growth factor (VEGF) pathway 
in modulating tumor angiogenesis and is increasingly viewed as an important therapeutic 
target. However, the specific effect of Notch inhibition on tumor endothelial cells, and perhaps 
consequently cancer stem cells, is poorly defined.
Emerging data suggests that glioblastoma stem cells may reside in a protective vascular niche that 
could contribute to cell fate decisions and survival [20]. Interactions between cancer stem cells 
and the vascular niche are thought to confer a survival advantage following therapeutic insults as 
well as allowing maintenance of the stem cell population and thus the ability to repopulate the 
tumor. A greater understanding of the role of the stroma in modulating malignant progression in 
glioma and other tumors has led to attempts at re-calibration of therapeutic strategies to target 
both cell autonomous and environmental factors.
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Laboratory studies of glioma biology have long relied on the use of dissociated glioma cell lines, 
which are evaluated in isolation form the tumor microenvironment. In view of the growing 
awareness of the role of the tumor stroma [21], specifically the vascular niche, to the integrity of 
the tumor stem cell pool, we optimized the organotypic or ‘ explant’ culture model in which the 
original cytoarchitecture, cell connectivity, and stroma—including blood vessels—are preserved 
[22, 23]. Using this system, we demonstrate that tumor endothelial cells are key components of 
Notch signaling in glioblastoma and likely mediate its effects on proliferation and self-renewal.
Materials and Methods
Culture of Primary Tumors as Organotypic/Explant Cultures
GBM tumor specimens were collected from the surgical suite and placed on ice in sterile 
phosphate-buffered saline (PBS). The tumor tissue was treated with RBC lysis buffer (eBioscience, 
San Diego, CA, ebioscience.com) to remove red blood cells and washed twice with ice-cold PBS. 
Using sterile 1 ml 27.5G syringes (BD Biosciences, San Jose, CA, http://www.bdbiosciences.
com), the tumor tissue was dissected under the microscope into ~1 mm3 pieces (explants). Five 
explants were placed on a sterilized culture plate insert (Millipore, Billerica, MA, http:// www.
millipore.com) that was pretreated with 1 μg/ml fibronectin (BD Biosciences, ) and placed in 
a 3-cm well. Culture media consisted of F12-DMEM (Gibco, Grand Island, NY, http:// www.
invitrogen.com) and N2 supplements (glucose, glutamine, sodium bicarbonate, 25 μg/ml of 
insulin, 100 μg/ml of human apotransferrin, 20 nM progesterone, 100 lM putrescine, 30 nM 
sodium selenite [all components from Invitrogen, Carlsbad, CA, http://www.invitrogen.com]) at 
a pH of 7.2 [24–26]. Sterile N2 media was added in the lower well and 10 ll of media were added 
to the surface of each explant. The media was changed every other day. Bromodeoxyuridine 
(BrdU; Sigma-Aldrich, St Louis, MO, http://www.sigmaaldrich. com, 10 lM) was added to the 
media 8 hours before harvesting.
Tissue Processing
Tissue was fixed in 4% p-formaldehyde overnight at 4oC, then transferred to 30% sucrose at 
4oC. Optimal cutting temperature compound (Sakura Finetek, Torrance, CA, http://www.
sakura- finetek.com) was used for embedding and 7 or 200 lm (for 3D reconstruction confocal 
microscopy) sections were cut on a cryostat (Leica, Deerfield, IL, http://www.leica-microsystems.
com).
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Fluorescence Immunohistochemistry
The sections were fixed with methanol for 5 minutes and permeabilized with acetone for 1 minute 
at -20oC. They were washed in PBS and blocked with 10% normal goat serum (Invitrogen) in 
PBS and 0.3% Triton X-100 for 1 hour. Primary antibodies were incubated overnight at 4oC 
and appropriate secondary antibodies (Alexa conjugates, Invitrogen) for 1 hour at 25oC. Slides 
were washed in PBS, counterstained with t-40,6-Diamidino-2-phenylindole (DAPI) (Invitrogen) 
and mounted in 70% glycerol or Prolong Gold anti-fade reagent (Invitrogen) for confocal and 
fluorescence microscopy. Antibodies included: Ki67 (1:100 Dako, Glostrup, Denmark, http://
www.dako.com), CD105 (1:100, Dako), CD31 (1:100, BD Biosciences), NICD (NICD 1:000, 
Abcam, Cambridge, MA, Cambridge, U.K., http://www.abcam. com) and Hairy and Enhancer 
of Split 5 (HES5) (1:100, Chemicon, Billerica, MA, http://www.chemicon.com). BrdU and 
terminal deoxynucleotidyl transferase deoxyuridine triPhosphate (dUTP) nick end labeling 
expression was measured using the 5- bromo-20-deoxy-uridine Labeling and Detection Kit I, 
and the POD (Horseradish peroxidase) In Situ Cell Death Detection Kit (both Roche Applied 
Science, Indianapolis, IN, http://www.roche- applied-science.com) according to manufacturer’s 
guidelines.
Image Acquisition and Histological Analysis 
Epifluorescence microscopy was performed using a BX51 microscope (Olympus, Center Valley, 
PA, http://www.olympus-global.com) equipped with a C4741-95 digital camera (Hamamatsu, 
Bridgewater, NJ, http://www.hamamatsu.com/). Images were processed using the SlideBook 4.2 
image software (Olympus). Confocal microscopy was performed using a Leica TCS SP2 AOBS 
laser scanning DMRXA2 microscope. The maximum intensity and blend projections of the 
stacked imaged were computed using Bitplane Imaris 4.5 software (Zurich, Switzerland, www.
bitplane.com). Thereafter, an isocontour model of blood vessels was generated to highlight the 
volume of the structures, then rotated, panned, and zoomed while recording the animation. The 
movie was later exported in .MOV format. Bright-field images were acquired using an Olympus 
IX71 microscope. Quantification of endothelial cells and ki67+ cells was performed on randomly 
selected high-power fields. On average, 4,000 cells per explant were counted.
Administration of Radiation and the γ-Secretase Inhibitor DAPT
The explants were allowed to attach to the insert overnight. A total of 25 µg/ml of the 
γ-secretase inhibitor DAPT (N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine 
t-butyl ester, Sigma-Aldrich) were added and media changed every other day. Radiation was 
delivered via X-RAD 225C irradiator (Precision X-Ray, Inc., North Branford, CT, http://
www.pxinc.com/). For the combination group, the explants were pretreated with 25 µg/ ml 
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DAPT for 5 days then irradiated with 10 Gy. DAPT was maintained in the media for the 
next 5 days.
Each experiment represents a minimum of three (range: 3–5) different tumors, each of which is 
represented in three wells. In average each condition thus consisted of a total of 9–15 explants 
per tumor, with a range of 3–5 tumors per experiment. Explants are pooled in groups of 3–5 
per well.
Neurosphere Assay and Flow Cytometry
The explants were dissociated into smaller pieces and placed in Hanks’ balanced salt solution 
(HBSS, Invitrogen) containing 1 mg/ml DNAse I (Roche Applied Science) for 15–30 
minutes at 37oC. The tissues were then triturated every 5 minutes and ultimately passed 
through a 35-µm cell strainer (BD Falcon, www.bd.com). The cells were washed using 
sterile 0.9 M sucrose in HBSS (pH 7.3) and resuspended in N2 media containing 20 ng/
ml basic fibroblast growth factor-2 and EGF (both from R&D Systems, Inc., Minneapolis, 
http://www.rndsystems.com). The cells were plated in ultralow attachment plates (Costar, 
Lowell, MA, www.colepalmer.com) at high density (20,000 cells per milliliter) for 3 days. 
Primary neurosphere formation was obtained readily but was often associated with nonviable 
clumps. After clearing agglutinating debris, we re-plated the cells at clonal density (100 cells 
per milliliter) and formed secondary neurospheres over 10–14 days.
For flow cytometry, the explants were dissociated in Liberase (400 µg/ml, Roche Applied 
Science). Cells were blocked with 1:10 FcR blocking reagent (Miltenyi, Auburn, CA, http:// 
www.miltenyibiotec.com) for 15 minutes at 4oC and labeled with CD133 antibodies (AC141 
and AC133 epitopes (1:1), Miltenyi) for 30 minutes at 4oC. Flow cytometry analysis was 
performed using FACSCalibur flow cytometer (BD, Franklin, NJ (bd.com)) and dead cells 
were excluded using 7-amino-actinomycin D (BD Pharmingen, San Diego, CA, http://
www.bdbiosciences.com/ index_us.shtml).
Clonogenic Assays
We established three different cell lines from fresh glioblastoma specimens [27, 28]. Briefly, 
surgical specimens were dissociated and cultured in N2 media under neurosphere conditions and 
different treatment conditions (DAPT, radiation and/or combination). Formed neurospheres 
were passaged for two to four times, and then dissociated and replated at clonal density (100 
cells per milliliter). To further confirm clonogenicity under attached culture conditions, cells 
replated on culture were coated with polyornithine, laminin, and fibronectin. Colony formation 
was visualized with gentian violet staining.
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Quantitative Real-Time Polymerase Chain Reaction
Total RNA was extracted using Trizol (Invitrogen). A total of 0.5 µg of RNA was reverse-
transcribed using SuperScript III First-Strand Synthesis System for reverse transcription-
polymerase chain reaction (RT-PCR) (Invitrogen). The resulting cDNA was subjected 
to real-time PCR amplification using Power SYBR Green PCR Master Mix (Applied 
Biosystems, Foster City, CA, http://www.appliedbiosystems.com). Primer sequences in 
supporting information Table 1.
Saporin-Conjugated Antibodies
The antibody CD105 (1:1,000) was incubated with goat antimouse IgG-saporin (ZAP, Advanced 
Targeting Systems, San Diego, CA, www.atsbio.com) in N2 media for 30 minutes at 37oC to 
allow binding and formation of a CD105 antibody-saporin complex [26], which was added 
to the explants or to hCMEC/D3 cell line (human cerebral microvessel endothelial cell line, 
courtesy of Babette Weksler) [29] used as control. Manufacturer directions were followed. As 
control, the CD105 antibody was incubated with a nontargeting goat IgG saporin that does not 
bind CD105. The antibody-saporin solution was injected into the explant under a dissecting 
microscope after gently incising the explant surface for better access.
VEGF Enzyme-Linked Immunosorbent Assay
VEGF into the culture media was measured as described previously [30], using a human VEGF 
enzyme-linked immunosorbent assay kit (Invitrogen).
Statistical Analysis
Statistical significance was determined using the student t-test (paired when indicated). p-values 
below .05 were regarded as significant. Errors are SEM. All experiments were performed in 
multiples (n = 3–5). Each n represents the number of independent tumors and a minimum of 
10 explants per tumor.
Results
The Tumor Microenvironment Is Preserved in the Explant Model of GBM
Our approach to the study of putative cancer stem cells in GBM was predicated on the 
maintenance of the tumor stem cell niche and tumor stroma including endothelial cells in vitro. 
To this end, we optimized a system for the culture of organotypic brain slices, first described by 
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Stoppini for the study of the hippocampus [23]. This model was designed originally for the study 
of normal physiological properties in the central nervous system.
Tumor tissue was obtained directly from the surgical suite and was dissociated into small 
pieces or ‘ explants,’ which were maintained in a transwell system, allowing their growth and 
maintenance in culture at an air-liquid interface. Chemically defined media was used without 
additional growth factors or sera. The explants survived well and were kept in culture for up to 
3 weeks with good viability. They flattened out and grew slowly over the course of a week (Fig. 
1A). The original cytoarchitecture was preserved with strong similarities between the parent 
tumor and its corresponding explant (Fig. 1B). This is best demonstrated in the preservation of 
tumor stroma, including a fibrillary GFAP+ background and tumor endothelium and pericytes 
(supporting information Fig. 1). Three-dimensional architecture was also preserved as seen in 
the maintenance of a highly branched appearance of the capillary network within the explant 
(3D-reconstructions in Fig. 1C and supporting information Movie). Endothelial hyperplasia 
and vascular glomeruloid bodies, highly characteristic features of GBM, were also preserved 
in explants (Fig. 1B, inset). Tumor cells in the explant exhibit a high proliferation rate as 
demonstrated by BrdU incorporation and Ki- 67 immunostaining (Fig. 1D). For a quantitative 
perspective, we analyzed the number of proliferating cells and of endothelial cells in sets of 
original tumors and their corresponding explants and found essentially identical values (Ki-
67 of 18.53% and 16.67% and CD105 of 10.13% and 9.29%,respectively). The process of 
explant culture is also highly efficient with the likelihood of successful explant derivation per 
tumor dissected exceeding 90% once protocols for tissue handling and culture were optimized. 
Occasionally explants containing significant areas of necrosis and pseudopalisades do not survive 
well and have to be discarded. Thus explants of glioblastoma maintain a significant similarity to 
the original tumor specimens.
We also analyzed variability within explants over the course of in vitro culture. Time course 
fluorescence-activated cell sorting analysis of four GBM samples on day1, day5, and day10 
revealed no time-dependent changes of CD133+ cells in the explants (n = 3 sets of explants for 
each time point, Fig. 1E). Time course analysis of in vitro uptake of BrdU over time also shows 
low variability that remains below statistical significance (p < .16) (supporting information Fig. 
2A). Immunohistochemistry for GFAP (Fig. 1F), Nestin, and CD133 (supporting information 
Fig. 2B) also shows minimal variability of expression over the course of 10–14 days.
This data suggests stability of tumor cell composition and marker expression as well as 
proliferation in our in vitro system over time.
Variability among tumors is a predictable element in this system, in view of the recognized genetic, 
vascular, and tumor cell heterogeneity in glioblastoma. A common occurrence is the variability 
of CD133 expression among different tumors (Fig. 1E) despite consistently rigorous gating. 
Exposure to radiation or chemotherapy treatments before surgery and specimen acquisition 
may result in significant selection and alterations in tumor response to in vitro. Stratification of 
tumors according to clinical and genetic variables is an area of intense research activity, which 
may lead to rapid testing and classification of GBM subtypes based on their transcriptome 
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Figure 1. The tumor microenvironment is preserved in the explant model of glioblastoma multiforme 
(GBM). (A): Bright-field image of GBM explants attached to a fibronectin-coated membrane. The explants 
flattened out and grew slowly over 7 days. (B): Hematoxylin and eosin staining of an explant at 7 days 
in vitro showing good preservation of cytoarchitecture and blood vessels, in comparison with its parent 
tumor. Inset shows a higher magnification of a glomeruloid body in both parent tumor and explant. (C): 
Immunohistochemistry for the tumor endothelial marker CD105 demonstrates maintenance of high 
vascularity. The three-dimensional structure of tumor vessels is demonstrated using a reconstruction of 
confocal immunofluorescence images of an explant in the right panel. CD31 labeling in red highlights the 
blood vessels, nuclei in blue (grid: 50 lm). (D): Explants maintain a high level of proliferation, shown 
here at 5 days in vitro, by immunohistochemistry for BrdU and Ki67. (E): Flow cytometry analysis of 
CD133 in explants from four different tumors. The number of CD133þ cells within each tumor showed 
little variabil- ity over 10 days in vitro (p > .05 for all four tumors). Tumors often exhibited significant 
heterogeneity for CD133 expression. (F): Immunofluo- rescence images of GFAP show a well maintained 
cytoarchitecture and no significant change in GFAP expression in the explants over 10 days in vitro. Error 
bars are SEM [Scale bars: 500 lm in (A) and (C); 100 lm in (B) and (F); 50 lm in (D)]. Abbreviations: 
BrdU, bromodeoxyuridine; DAPI, 40,6-diamidino-2-phenylindole; GFAP, Glial Fibrillary Acidic Protein.
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and/or proteome profiles [31]. In this manuscript, a total of 23 tumor specimens were used, 
originating from nine male and 14 female patients, of whom nine had recurrent tumors and 14 
were newly diagnosed. All tumors were WHO grade IV glioblastomas with one tumor known 
to have progressed from a previous WHO grade III anaplastic astrocytoma. All but one of the 
recurrent tumors had received irradiation and temozolomide at the time of tissue collection. 
Limited clinical cytogenetics data were available for 19 of 23 specimens (supporting information 
Table 2).
Notch Inhibition Decreases Self-Renewal in GBM Explants
Recent data suggests a role for Notch pathway in maintenance of self-renewal by CD133+ cells 
in vitro. We analyzed the impact of Notch inhibition on GBM by exposing the tissue explants to 
the γ-secretase inhibitor DAPT for 5 days. To analyze the impact of Notch inactivation on self-
renewal, we performed secondary neurosphere formation assays at clonogenic density. Five days 
after continuous DAPT treatment, the explants were dissociated and placed under neurosphere 
conditions. A significant decrease in secondary neurosphere formation by an average of 84% 
was observed after DAPT treatment, compared with controls (n = 3, p = .0018) (Fig. 2A, 2B). 
Figure 2. Notch inhibition decreases the number and function of stem cells in glioblastoma multiforme (GBM) 
explants. (A, B): After 5 days of DAPT treatment, the explants were dissociated into single cells and grown under 
neurosphere conditions. A significant (84%) decrease in secondary neurosphere formation was observed [in (B), p 
= .0018]. (C, D): Flow cytometry analysis for CD133 in DAPT treated explants. Despite large variabil- ity in % 
CD133þ cells among the primary GBM tumor samples, there was a consistent relative decrease in the number of 
CD133þ cells averaging 50% on treatment with the Notch inhibitor and in comparison with controls. Scale 
bar in (A): 200 lm. Error bars are SEM. Abbreviations: DAPT, N- [N-(3,5-difluorophenacetyl)-L-alanyl]-S-
phenylglycine t-butyl ester; DMSO, dimethyl sulfoxide; FITC, fluorescein isothyocyanate; PE, phycoerythrin.
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This was associated with a parallel decrease in the number of CD133+ cells as demonstrated 
by flow cytometry studies. Although the percentage of CD133+ cells varied among tumors, 
the relative decrease was very consistent (48– 53%) (Fig. 2C, 2D). These findings suggest that 
inhibiting Notch results in a decrease in self-renewal potential of tumor cells as well as a decrease 
in the number of CD133+ cells or downregulation of CD133 expression. The overall effect is 
compatible with a decrease in stem cell-like potential within the tumor explants.
The Effects of Notch Inhibition Is Mediated by the Loss of Endothelial Cells
The Notch pathway plays a key role in development and in the regulation of angiogenesis. The 
NICD and the downstream target gene, Hes5, follow a vascular and perivascular expression 
pattern in tumor explants as well as parent tumor tissue (supporting information Fig. 3A). 
Treatment of explants with DAPT for 5 days resulted in a loss of the CD105 expressing cells 
averaging 50% decrease but reaching up to 75% in some tumors (range: 1.1- to 4.1-fold decrease, 
p = .0001) as seen by immunohistochemistry and RT-PCR (Fig. 3A, 3B). Other endothelial 
Figure 3. Notch inhibition exerts its effect in part by targeting endothelial cells. Following Notch inhibition 
with DAPT explants exhibit a decrease in expression of the endothelial marker CD105 as demonstrated 
by qRT-PCR [(A) 3.8-fold decrease, p = .004] and immunohistochemistry (B). (C): Downregulation of 
Notch target genes HES1 and HES5 (p = .0071 and p = .00004, respectively) on DAPT administration. 
(D): Immuno- histochemistry for secondary neurospheres shows the absence of endothelial cells (CD105) 
and mesenchymal markers (CD73). Neurospheres are immunopositive for nestin and partially for CD133 
(data not shown). Scale bars 100 lm in (A); 200 lm in (D). Abbreviations: DAPI, 40,6-diami- dino-
2-phenylindole; DAPT, N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester; DMSO, 
dimethylsulfoxide; HES1, Hairy and enhancer of split 1; HES5, Hairy and enhancer of split 5; qRT-PCR, 
quantitative reverse transcription-polymerase chain reaction.
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markers such as CD31, von Willebrand factor, and CD146 were also decreased (data not shown). 
This data suggest an antiangiogenic effect of Notch blockade with subsequent disruption of 
the vascular niche in the explants. The Notch downstream target genes HES1 and HES5 were 
significantly downregulated as expected (Fig. 3C). This effect was very consistent in all GBM’s 
tested and reflects effective inhibition of Notch signaling. In view of the concomitant decrease 
in neurosphere formation as a consequence of Notch inhibition, we evaluated the secondary 
neurospheres for expression of endothelial or other stromal markers, specifically CD105 and 
CD73, and found them to be negative. Most neurosphere cells stained for nestin and CD133 
(Fig. 3D).
Having shown above that Notch inhibition results in a decrease in neurosphere formation and 
CD133+ cells, we tested the hypothesis that it was in fact the effect on endothelial cells that 
mediates the decrease in brain tumor stem cell number and function.
We used a conjugated antibody system that targets CD105 (endoglin), a tumor endothelium 
marker that is widely expressed in glioblastoma [32, 33] and explants (Fig. 1C).
Anti-CD105 antibody is conjugated to a saporin toxin that is released in the cell on internalization 
of the antibody complex, resulting in cell death via ribosomal inhibition [34]. A brain endothelial 
cell line highly expressing CD105 (hCMEC, courtesy of Weksler) was used as a control and for 
dose optimization of the saporin-conjugated antibody. Significant cell death (37% compared 
with controls, p = .028) was obtained within 5 days of exposure to the anti-CD105 saporin 
complex (Fig. 4). Subsequently, explants were treated with anti- CD105-saporin for 5 days. 
Control explants received the CD105 antibody preincubated with a nontargeting goat IgG 
saporin complex. A selective and significant decrease in endothelial cells was observed in the 
Figure 4. CD105-ZAP effectively kills human brain endothelial cells. The human brain endothelial cell line 
hCMEC expresses CD105 (red). Treatment with the anti-CD105 antibody conjugated to the saporin toxin 
but not the untargeted control resulted in cell death of the majority of human cerebral microvessel endothelial 
cell line (hCMEC) cells. The mitochondria activity based MTT assay confirmed this significant reduction 
in viability (44.9% reduction (6 11.6%), n = 3, p = .029, error bars represent SEM). Scale bars 25 µm. 
Abbreviations: DAPI, 40,6-diamidino-2-phenyl- indole; MTT, 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyl 
Tetrazolium Bromide; ZAP, saporin immunoconjugate.
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treated explants (p = .0024) as shown by immunohistochemistry and quantitative reverse 
transcription-polymerase chain reaction (qRT-PCR) (Fig. 5A). Other endothelial cell markers 
such as CD31 were also decreased. This was associated with a significant downregulation of the 
Notch effector Hes5 by 60% compared with untreated controls (Fig. 5B). Interestingly, the loss 
of endothelial cells resulted in a decrease in neurosphere-forming ability to <50% of controls (p 
= .04) (Fig. 5C). CD133 expression was analyzed by qRT-PCR and was found to be essentially 
unchanged (supporting information Fig. 3B). Flow cytometry post-ZAP treatment was very 
suboptimal possibly due to crossreaction between the saporin-conjugated anti-CD105 and the 
anti-CD133 antibodies, both being IgG1 isotypes. This was further associated with a decrease 
in secretion of VEGF into the media, similar in magnitude to that seen under conditions of 
pharmacological inhibition of Notch (Fig. 5D). Thus the loss of endothelial cells mimicked a 
Notch inhibition like state and reduced self-renewal suggesting that the mechanism underlying 
the effects of Notch blockade involves disruption of the vascular niche. The reduction in VEGF 
Figure 5. Effect of selective elimination of endothelial cells in glioblastoma multiforme (GBM) explants. (A): 
Treatment with the CD105-saporin complex reduces endothelial cells as shown by immunohistochemistry and 
mRNA levels for CD105 (2.9-fold decrease, p = .001). (B): A decrease in HES5 transcript was observed as well 
after 5 days treatment with the CD105-saporin complex (right panel, 2.5-fold decrease, p = .002) suggest- ing 
suppression of Notch activity as a consequence of the loss of endothelial cells. (C): Disruption of the CD105þ 
endothelial cell population results in a significant decrease in neurosphere-forming ability and a tendency 
toward formation of smaller spheres. (D): Vascular endothelial growth factor (VEGF) secretion in the media was 
measured by enzyme-linked immunosorbent assay. Pharmacological suppression of Notch activity resulted in a 
decrease of VEGF secretion in the media of a similar magnitude to that seen after the CD105-saporin mediated 
loss of endothelial cells (30% decrease with and 43% decrease, respectively, p = .038). Scale bars: 100 lm in (A); 
50 lm in (B); 200 lm in (C). Error bars represent SEM. Abbreviations: DAPI, 40,6-diamidino-2-phenylindole; 
DAPT, N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester; HES5, hairy and enhancer of split 
5; qRT-PCR, quantitative reverse transcription-polymerase chain reaction; ZAP, saporin immunoconjugate.
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may be the result of the loss of endothelial cells although the possibility of an inhibitory effect by 
Notch on the VEGF pathway cannot be ruled out.
Notch Inhibition Enhances the Effect of Radiation in GBM Explants but not 
GBM Cultures
The impact of radiation on GBM is often studied in cell lines in vitro, and their radiation resistance 
is well documented, but the response of tumor cells within their native microenvironment is not 
well studied. This is particularly relevant in view of the data supporting a role for endothelial cells 
in supporting self-renewing cells in some brain tumors [6]. Explants
from five different GBM specimens were pretreated with DAPT for 5 days followed by radiation 
with a single dose of 10 Gy. They were compared with explants from the same specimens 
receiving a single treatment (radiation or Notch) and untreated controls. The experiment was 
conducted over 10 days, to allow a 5-day pretreatment with the Notch inhibitor preceding 
radiation. Data analysis was performed 5 days postradiation. Single treatments, via DAPT or 
radiation, reduced proliferation in the explants by 50%. However, the combination of DAPT 
and radiation had a more profound effect, dramatically reducing the proliferation rate from 
14.3% to 3.4% (Fig. 6A, 6B). Neurosphere formation was tested in all treatment and control 
groups (Fig. 6C, 6D). Notch inhibition resulted in a significant decrease in neurosphere-forming 
ability compared with controls (p = .027), whereas radiation alone did not have a statistically 
significant impact (p = .450). However, the combined treatment was most effective, reducing 
neurosphere formation from 28.57% in controls and 13.12% in DAPT alone to 8.12% (p = 
.014 and .018, respectively). The number of CD133+ cells decreased dramatically to 23.69% 
of control after DAPT and 33.42% after radiation (p =  .013 and .011, respectively) (Fig. 
6E). The combination treatment also resulted in a significant decrease compared with control 
(23.48% of the control value, p = .041). Although the combination group was more effective 
than radiation alone, its impact did not reach statistical significance (p = .2).
In comparison, we performed similar experiments on glioblastoma neurospheres dissociated from 
primary tumors and passaged for short periods (P2–P4). As noted previously, such neurospheres 
consist of nestin+ cells and are negative for endothelial or mesenchymal stroma cells. Neurosphere 
cultures were treated with DAPT, XRT or a combination, for the same duration of time as the 
explants, passaged and replated at clonogenic density. The impact on cell growth was analyzed 
by dissociating the spheres into single cells and analyzing surviving cell numbers. Our data shows 
a significant decrease in cell number in response to DAPT, and a more substantial decrease in 
the radiation and combination groups (supporting information Fig. 4A). Neurosphere formation 
was also dramatically reduced after radiation and the combination (from 18.8/1,000 cells to 
1.9 and 1.5 neurosphere/1,000 cells plated in the radiation and combination groups, respectively, 
supporting information Fig. 4B). The number of CD133+ cells was highly variable among the 
tumors studied and trended down most significantly in response to the combination treatment 
(supporting information Fig. 4C). In comparison with the explant data, the impact of radiation 
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Figure 6. Notch inhibition enhances the effect of radiation in glioblastoma multiforme (GBM) explants. (A): 
Immunohistochemistry for Ki-67 (red) in explants exposed to DAPT, radiation or a combination treatment, 
demon- strating an antiproliferative response in all treatment conditions. (B): A quantitative assessment of the 
percentage of Ki-67þ dem- onstrates a decrease from14.3 6 0.67% to 7.2 ± 1.19% and 7.3 6 1.49% following 
DAPT and radiation, respectively. The combination treatment reduced Ki-67-3.4 6 0.98%. p = .003 (vs. DAPT), 
p = .004 (vs. radiation) and p < 10-8 (vs. control). (C, D): Neurosphere- forming ability in control and 
treatment condi- tions demonstrates a lack of effect by radia- tion, while DAPT consistently reduced 
neurosphere formation. The combination treat- ment showed a more potent effect reducing neurosphere 
formation from 28.57% to 8.12% in controls. (E): Flow cytometry analysis of CD133 revealed a dramatic 
decrease in the combination treatments (23.5%, p = .041), but the effect was not significantly different com- 
pared with DAPT or radiation alone. Scale bars: 50 µm in (A); 200 µm in (C). Errors rep- resent SEM. 
Abbreviations: DAPI, 40,6-diami- dino-2-phenylindole; DAPT, N-[N-(3,5- difluorophenacetyl)-L-alanyl]-
S-phenylglycine t-butyl ester.
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alone on cell number and self-renewal in the dissociated cell group is much more significant 
and is not enhanced by Notch inhibition. The increased resistance to radiation seen within the 
explants may be due to a variety of factors, including a protective role of the intact vascular niche 
on the tumor stem cells. It should be noted that unlike Notch inhibition, radiation treatment 
alone does not reduce the number of endothelial cells within explants (supporting information 
Fig. 3C,D). A more robust response to radiation is seen in the explants only in combination with 
loss of endothelial cells on Notch inhibition. In explants, there was a concomitant decrease in 
proliferation and the number of CD133+ cells in the group receiving radiation and yet an intact 
rate of neurosphere formation, suggesting that radiation alone does not impact putative cancer 
stem cell function. Alternatively, neurosphere-forming stemlike cells in situ may not always be 
CD133+, an observation with growing support in the literature.
Although the response to radiation is complex and warrants further investigation, this data 
supports a role for the microenvironment, specifically endothelial cells, in modulating the 
response to radiation and Notch inhibition. It further emphasizes the advantages of analyzing 
tumor response in vitro within the context of the tumor stroma.
Discussion
Studies using glioblastoma cell lines have long suffered from poor reproducibility in view of 
recognized alterations in genomic profiles and in vitro behavior. Work on cell lines or 
neurospheres highlights specific subpopulations of cells but fails to analyze the interactions 
among cell species within a tumor. This is particularly relevant in the case of the Notch 
pathway where cell-to-cell interactions play a key role in ligand availability and receptor 
activation. The effects of Notch signaling are highly context dependent and have thus to 
be analyzed for individual cell types in specific microenvironments. In addition, there is 
emerging data that suggests that tumor stem cells reside in a perivascular niche structurally 
and functionally. Here, we show that the organotypic explant model is a useful tool for 
studying GBM biology. The preservation of blood vessels and cell connectivity in their 
original context offer a definite advantage over the more commonly used cell lines 
or tumor sphere systems. The dual effect of Notch inhibition on the tumor stem cells 
and on endothelial cells as illustrated here could not be demonstrated in cell lines 
or xenografts, which may recruit host-derived endothelial cells. Thus our organotypic 
model is exquisitely suitable to study the biology of glioblastoma and to model therapeutic 
response in vitro. The description of stem-like cells in brain tumors and their potential 
contribution to therapeutic failure has led to significant expansion of research in this area 
[4]. The concept of cancer stem cells implies a hierarchical organization within the tumor, 
whereby tumor initiation and repopulation after cytotoxic therapy is ascribed to a small 
subpopulation of tumor cells. Although controversy remains about their lineage, phenotypic 
identification, and precise function [5], tumor stem cells are often defined in vitro as 
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CD133-expressing cells with neurosphere-forming ability. However there is growing data 
to support that neurosphere formation, self-renewal and tumor formation is not exclusive 
to CD133 expressing cells. The expression of this marker whose physiological function 
remains unknown may also be dynamic and is likely dependent on culture conditions. It 
has also been suggested that the similarities between cancer stem cells and normal stem 
cells could be due to tumor initiation in the normal stem cell compartment, rather than 
dedifferentiation of more mature cells [9, 35–37]. These data stress the importance of 
identifying pathways that specifically target the stem cell-like cell populations.
The Notch pathway is a particularly attractive candidate due to its key role in promoting self-
renewal in normal neural stem cells [15] as well as its involvement in angiogenesis. In fact Notch 
signaling has been invoked as a possible mediator of refractoriness to antiangiogenic agents that 
target the VEGF pathway [38]. The impact of Notch activity in glioblastoma is not completely 
defined. Some data suggest a role in proliferation [39, 40] and several Notch components are 
frequently upregulated in GBM transcriptomes [41]. More recent data suggest that Notch inhibition 
depletes CD133+ cells in glioblastoma and promotes increased responsiveness to radiation [42, 43]. 
Data in medulloblastoma cell lines [43] also suggested that Notch inhibition results in depletion of 
stem-like cells and a decrease in tumor forming capacity. In our experiments, Notch inhibition in 
GBM explants resulted in a decrease in the number of putative cancer stem cells and in self-renewal, 
compatible with literature reports. However, it also led to a decrease in endothelial cells suggesting a 
possible relationship between an intact endothelial compartment and the stem cell or self-renewing 
population. In fact the selective elimination of endothelial cells from the explants resulted in a state 
highly similar to pharmacological Notch inhibition, with downregulation of Hes5 and a decrease in 
neurosphere-forming ability and CD133 cells. These data suggest that the suppression of cancer stem 
cell function and number is at least in part mediated by endothelial cells and that the effect of Notch 
inhibition may be in part secondary to its antiangiogenic effect. They also highlight the advantages 
of analyzing tumor response to pathway manipulation within its original microenvironment. Current 
literature supports the coexistence of tumor stem cells within a vascular niche [6] that could provide 
a survival and functional advantage for tumor repopulation. Endothelial cells also play a critical role 
in the maintenance of self-renewal and the neurogenic potential of normal neural stem cells [16, 44]. 
Further studies are required to further characterize the role of Notch signaling in modulating the 
interaction of endothelium and tumor stem cells.
Additional experiments also highlighted differences in response to radiation between the explants 
and dissociated tumor cells. There was a more significant response to radiation by the neurosphere 
cultures in comparison with the explants. Radiation alone had a modest impact on self-renewal 
capacity in the explants and did not lead to a significant change in endothelial cells. The addition 
of Notch blockade potentiated the explants’ response to radiation but had a minimal effect 
on the dissociated cells. This again highlights the role of the microenvironment, specifically 
endothelial cells in modulating the response to radiation. It could also reflect the existence of 
heterogenous GBM cell subpopulations in the explants, such as neurosphere-forming cells that 
are either noncycling under homeostatic conditions or capable of bypassing radiation damage 
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rapidly. This finding is compatible with clinical data whereby GBMs commonly exhibit a stable 
to a minor decrease in tumor volume followed by local recurrence after radiation. Resistant 
or previously non cycling stem-like cells may then re-enter the cell cycle and repopulate the 
tumor. An important caveat to this data interpretation is the possibility of selection of specific 
subpopulations under neurosphere culture conditions. In some of the experiments, there was a 
dissociated response between the number of CD133+ cells and neurosphere-forming ability. This 
may be in part due to the large variability of CD133 expression among tumors, but could also 
have implications as to the significance of CD133+ alone as a unique stem cell marker. Recent 
data suggest CD15 as a candidate marker for putative glioma stem cells [45], but that remains to 
be more extensively validated.
Notch inhibition can be achieved at various levels, including blocking ligand ubiquitination, 
altering receptor activation or more directly interfering with downstream events. Monoclonal 
antibodies that target Notch ligands such as DLL4 or that inactivate Notch receptors have 
also been described. Gamma-secretase is a member of the I-CLIP protease family that has 
numerous transmembrane targets other than Notch receptors and what has been referred to as 
‘‘promiscuous cleavage specificity’’ [46]. In addition to Notch and its ligands, it can also target 
Erb-B4, E- and N-cadherins, CD44, the low-density lipoprotein receptor and Nectin-1 [47]. 
Most of the available gamma-secretase inhibitors (GSI), including DAPT, have no preference 
for substrates, as is commonly observed for small molecule inhibitors/drugs. However, there are 
ongoing efforts to modify known inhibitors and allow greater affinity to specific target substrates. 
These efforts are particularly active in the Alzheimer field where there are reports of compounds 
(such as NSAIDs [48] or coumarindimer based molecules [49]) that can selectively target 
Ab42 (amyloid b precursor protein) thus alleviating the potential long-term toxicity of global 
γ-secretase inhibition. Nonetheless several nonspecific GSI molecules are currently in clinical 
trials for different cancers. Alternate and potentially more specific means of blocking the Notch 
pathway are under development, such as monoclonal antibodies that target the Notch receptors 
or ligands and targeted tumor delivery.
From a therapeutic perspective, by targeting the stem cell and the endothelial compartments, 
Notch inhibition addresses two prime targets: tumor repopulation and angiogenesis. Our data 
suggest that the effect of radiation is clearly enhanced when carried out in a background of Notch 
inhibition. In the absence of Notch signaling, tumor stem cells loose their selfrenewal ability and 
likely transit into a progenitor-like state that is more vulnerable to radiation. Future studies will 
address the in vivo role of combined radiation and Notch inhibition.
Conclusion
We have presented a novel adaptation of the organotypic culture system to the study of 
glioblastomas. The three-dimensional explant system preserves tumor cytoarchitecture and 
stroma including endothelial cells. This has allowed us to demonstrate that Notch inhibition also 
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results in a decrease in the number of endothelial cells within the tumor, which likely disrupts the 
perivascular niche harboring tumor stem cells. In fact selective elimination of endothelial cells 
via an antibodytoxin conjugate resulted in a Notch-inhibition like state and a decrease in self-
renewal, suggesting that endothelial cells play an important role in tumor stem cell maintenance 
that is at least partially mediated by Notch signaling. The explant system further highlighted 
differences in the response to radiation between explants and isolated tumor neurospheres. 
Combination treatment with Notch blockade and radiation resulted in a substantial decrease 
in proliferation and in self-renewal in tumor explants whereas radiation alone was less effective. 
This data suggests that the Notch pathway plays a critical role in linking angiogenesis and cancer 
stem cell self-renewal and is thus a potential therapeutic target. Three-dimensional explant 
systems provide a novel approach for the study of tumor and microenvironment interactions.
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Supplemental Figure 1. Immunohistochemistry sections of tumors and their corresponding explants demonstrate 
a fibrillary background and comparable GFAP and Nestin labeling. Scale bars are 50 µm in the upper panels and 
25 µm in the lower panels.
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Supplemental Figure 2. Assessment of timedependent changes in explants cultured in vitro. A, Explants 
maintained a high level of proliferation rate shown by immunohistochemistry for BrdU (Error bars are SEM; 
ANOVA, p=0.61). B, Minimal variation was seen in the cytoarchitecture of the explants over 10 days in vitro 
as assessed by fluorescence immunohistochemistry for CD133 and nestin. Scale bars are 100 µm.
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Supplemental Figure 3. A, The notch effectors NICD and HES5 are highly expressed around blood vessels 
in GBM. Fluorescence immunohistochemistry demonstrating the perivascular expression of NICD or Hes 
5 (green) around CD105+ endothelial cells (red), in a GBM explant (DAPI nuclear stain in blue). Scale 
bars: left, 50 µm; right, 100 µm). B, CD133+ cells could only be analyzed by qRTPCR which showed no 
significant changes after treatment with antiCD105saporin for 5 days (n=3, p=0.73). C and D, Radiation 
alone had no effects on CD105+ endothelial cells as assessed by fluorescence immunohistochemistry for 
CD105 and qRTPCR (n=3, p=0.50).
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Supplemental Figure 4. The impact of Notch inhibition and radiation on isolated glioblastoma cells. A, All three 
treatments resulted in a significant decrease of cell growth (vs control), but DAPT did not significantly enhance 
the effect of radiation (radiation vs DAPT + radiation, p=0.06). B, Neurosphere formation was significantly 
decreased by radiation, but not by DAPT (vs control). Combination with DAPT did not significantly enhance the 
effect of radiation (radiation vs DAPT + radiation, p=0.77). C, CD133+ cells showed a decrease following each 
treatment with the combination treatment being most effective, but no significance was detected compared to the 
effect of radiation alone (radiation vs DAPT + radiation, p=0.44). D, Bright field images of clonogenic colonies 
visualized by gentian violet staining. Scale bar: 1mm.
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Supplementary Table 1
β-actin Fw CACAG AGCCT CGCCT TTGCC
β-actin Rv CACAT GCCGG AGCCG TTGTC
HES5 Fw CCCGG GGTTC TATGA TATTT G
HES5 Rv GCCCT GAAGA AAGTC CTCTA CA
HES1 Fw TTACG GCGGA CTCCA TGT
HES1 Rv AGAGG TGGGT TGGGG AGT
CD105 Fw GCGGT GGTCA ATATC CTGTC
CD105 Rv GTTGAG GCAGT GCACC TTTT
CD31 Fw TTCCT GACAG TGTCT TGAGT GG
CD31 Rv GCTAG GCGTG GTTCT CATCT
CD133 Fw TGACC CTCTG TGCTT GGTGC
CD133 Rv TGGAA GCTGC CTCAG TTCAG GG
Supplemental Table 1. Primer sequences used in the manuscript.
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Supplementary Table 2 Tumors used in the study
Tumor Gender Age Stage
Radiation
Therapy*
EGFR
amplification Other Experiments
GBM1 M 69 new no n/a
Tumor microenvironment DAPT 
on explant
CD105-ZAP on explant DAPT 
and XRT on explant
XRT on explant
GBM2 F 35 recurrent no n/a
Prog re s s ed 
from AA
Tumor microenvironment DAPT 
and XRT on explant
GBM3 F 63 new no 45% Tumor microenvironment
GBM4 F 49 recurrent yes n/a
Prog re s s ed 
from AA
Tumor microenvironment DAPT 
on explant
CD105-ZAP on explant Tumor 
microenvironment
GBM5 M 70 new no n/a
Tumor microenvironment DAPT 
on explant
DAPT and XRT on cell line
GBM6 M 27 recurrent yes no Explant time course
GBM7 F 52 new no 100% Explant time course
GBM8 F 32 recurrent yes no
Explant time course
DAPT on explant
GBM9 F 82 new no no DAPT on explant
GBM10 M 53 recurrent yes 78%
DAPT on explant CD105-ZAP 
on explant
DAPT and XRT on explant
GBM11 M 52 new no 98%
DAPT on explant
DAPT and XRT on explant
GBM12 F 69 new no n/a
DAPT on explant CD105-ZAP 
on explant
GBM13 M 62 new no no DAPT on explant
GBM14 M 63 recurrent yes no
5 3 % 
amplification 
of CMS 7
DAPT on explant CD105-ZAP 
on explant
DAPT and XRT on explant
GBM15 F 73 new no 95% DAPT on explant XRT on explant
GBM16 M 45 recurrent yes 60% DAPT on explant
GBM17 F 81 new no no
CD105-ZAP on explant DAPT 
and XRT on explant
GBM18 F 64 new no no
5 3 % 
amplification 
of CMS 7
CD105-ZAP on explant
GBM19 F 62 recurrent yes no
T r i s o m y 
CMS 7 in 
12.5%
DAPT and XRT on explant 
Explant time course
GBM20 M 73 new no no
6 3 % 
amplification 
of CMS 7
DAPT and XRT on explant
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Tumor Gender Age Stage
Radiation
Therapy*
EGFR
amplification Other Experiments
GBM21 F 38 new no 64% DAPT and XRT on explant
GBM22 F 57 new no no
DAPT and XRT on explant 
DAPT and XRT on cell line
GBM23 F 47 recurrent yes 92% DAPT and XRT on cell line
(AA) Anaplastic Astrocytoma (WHO, grade III)
(*) Radiation therapy was administered to all patients concomitantly with Temozolomide
7Chapter 7
General Discussion  
and Valorization
 
Angiogenesis inhibition  
in glioblastoma
Chapter 7114 |
Discussion
Due to its high vascularity the malignant brain tumor glioblastoma has been viewed as an 
ideal target for anti-angiogenesis therapy like bevacizumab. Randomized controlled trials to 
date unfortunately only showed a modest and unsustained impact on disease progression1,2 . 
Nonetheless bevacizumab continues to be used, especially in recurrent settings and in many 
clinician experiences some patients do seem to respond to the treatment next to the advantage of 
diminished need for steroids to reduce tumorassociated edema. The tumor micro-environment, 
that shelter the so-called brain tumor stem cells3, plays an important role in the resistance to 
anti-angiogenic treatment. The goal of this thesis was therefore further the understanding on 
the evasive mechanisms, particularly in the tumor micro-environment, that glioblastoma uses 
to overcome the resistance to anti-angiogenic treatment. By that I hoped to be able to identify 
patients that are more or less likely to respond to this treatment. An additional goal was to offer 
alternative ways of angiogenesis inhibition to make this an effective treatment for patients with 
glioblastoma. Which is the central hypothesis of this thesis.
VEGF secretion increases after radiation in glioblastoma cell lines.
Postoperative radiotherapy is standard treatment for patients with glioblastoma, however 
despite high does radiation the tumor inevitably recurs. Due to high levels of secreted VEGF, 
glioblastoma is known for its extensive neo-angiogenesis. In the first chapter we investigated the 
VEGF secretion by glioblastoma cells with different radiosensitivity after irradiation. We showed 
that radiation induces a dose-dependent increase in VEGF- secretion in three glioblastoma cell 
lines lines: U87, U251 and U251-NG2 4. Interestingly we did not find a decrease in cell number 
after irradiation, even after irradiation with as high as 20 Gy, which confirms high radioresistance. 
Since the cell line U87 was most resistant to irradiation and had the highest basal VEGF 
secretion it is tempting to suggest that enhanced VEGF secretion is involved in radioresistance. 
We concluded that irradiation induces significant enhancement of VEGF-secretion, which 
appears to be a general response in GBM cell lines we tested. Therefore we speculate that the 
radiationenhanced VEGF-secretion decreases apoptosis and increases angiogenesis, both leading 
to GBM radioresistance. Angiogenesis inhibition can therefore be considered as an adjuvant for 
existing therapies for glioblastoma like radiotherapy.
Classical subtype and EGFR amplification are associated with a poor 
response to bevacizumab in the recurrent setting.
In chapter two we tried to identify patients that are likely to respond better or worse to anti-
angiogenic therapy in glioblastoma, we analyzed the molecular profile of a cohort of patients 
at memorial Sloan-Kettering center that received bevacizumab for recurrent glioblastoma. Our 
data suggested that patients with recurrent glioblastomas that exhibit EGFR amplification or 
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classical subtype per TCGA classification were associated with a shorter time to progression on 
bevacizumab, in comparison to tumors with a proneural, neural and mesenchymal subtype or 
tumors without EGFR amplification. Patients with a classical subtype had a median time to 
progression of only 2.8 months compared to 5.1 in the mesenchymal, 6.4 in the neural and 6.0 in 
the proneural subtypes. In patients with EGFR amplified tumor, the median time to progression 
was 3.7 months compared to 6.7 months in tumors that did not have EGFR amplification5. A 
worse outcome in EGFR- amplified and classical tumors was statistically significant on both 
univariate and multivariate analysis5. It is interesting to note that some patients with mesenchymal 
tumors seemed to do better on bevacizumab. In a few cases some patients managed to stay on 
this treatment for more than 18 months, suggesting that the mesenchymal subtype may be more 
suitable to this treatment. This is especially promising since this subtype was shown to have the 
worst prognosis and recurrent tumors have often shown a switch to this subtype6. These findings 
suggest that careful consideration should be given before starting recurrent glioblastoma patients 
on bevacizumab if the tumor is EGFR-amplified or exhibits a TCGA classical subtype. This is 
especially important since it has become evident in recent years that bevacizumab treatment is 
not without risk, in particular from wound breakdown and the possibility of inducing a more 
infiltrative aggressive tumor after treatment 7.
Brain tumor stem cells can form endothelial cells
Although debatable, a small subset of cells in glioblastoma that express the cell surface glycoprotein 
CD133, that is also expressed in hematopoietic stem cells, seem to have some characteristics 
that qualifies them as brain tumor stem cells or BTSC 8. In chapter three we show that in a 
number of glioblastoma samples the stem-cell-like CD133+ fraction includes a subset of vascular 
endothelial-cadherin (CD144)-expressing cells that show characteristics of endothelial progenitors 
capable of maturation into endothelial cells. Interestingly a subpopulation of endothelial cells 
within glioblastomas harbor the same somatic mutations identified within tumor cells, such as 
amplification of EGFR and chromosome 7 centromere. Extensive lineage analyses, including 
single cell clonal studies, further showed that a subpopulation of the CD133+ stem-like cell 
fraction is multipotent and capable of differentiation along tumor and endothelial lineages, 
possibly via an intermediate CD133+/CD144+ progenitor cell. We were able to demonstrate 
identical genomic profiles in the CD133+ tumor cells, their endothelial progenitor derivatives 
and mature endothelium further supporting the concept that endothelial cells can be formed 
by BTSC. When we exposed tumor samples to bevacizumab as well as by knockdown shRNA 
studies, we could demonstrate that blocking VEGF or silencing VEGFR2 inhibits the maturation 
of tumor endothelial progenitors into endothelium but not the differentiation of CD133+ cells 
into endothelial progenitors9. In clinical practice bevacizumab therapy is often interrupted by 
GBM progression characterized by a decrease in abnormal vascularity and significant invasive 
tumor behavior 10. It is therefore conceivable that bevacizumab failure is due to the disruption of 
the dynamic relationships between these tumor fractions.
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Brain tumor stem cells can be studied in an organotypic “explant” model
Emerging data suggests these brain tumor stem cells may reside in a protective vascular niche that 
this proximity to blood vessels could contribute to cell fate decisions and survival 3. Interactions 
between cancer stem cells and the vascular niche are thought to confer a survival advantage 
following therapeutic insults as well as allowing maintenance of the stem cell population and 
thus the ability to repopulate the tumor. The commonly used preclinical models of glioblastoma 
cell lines are frequently passaged in various culture media at high proliferation rates, resulting in 
significant genetic and molecular alterations. This has led to the realization that data obtained in 
cell lines are often inapplicable to patient tumors. Furthermore, since the vascular niche seems 
to play a crucial role for BTSC and therefore tumor growth 3,8, this dynamic relationship can 
not be reproduced in cell line cultures. In chapter four we show a novel three-dimensional 
organotypic “explant” system of surgical GBM specimens that preserves tumor cells in their 
original milieu, as well as the cytoarchitecture of the tumor stroma11. In this model, tumor tissue 
obtained directly from the operation room is dissected into small pieces called “explants” and 
are maintained in an air-liquid interface on semiporous membranes. This model was originally 
designed for the study of normal physiological properties in central nervous tissue slices12. For 
the GBM explant culture, we use chemically defined media without additional growth factors or 
sera13, to avoid selective growth of stem/progenitor cell population or their differentiation that 
allows the study of BTSC. The GBM explants are maintained for a relatively short period (up to 
three weeks) before they are harvested for downstream analyses including immunohistochemistry, 
flow cytometry, and neurosphere assay. In our opinion this model is ideally equipped to study the 
BTSC niche and their pathways that can lead to therapeutic targets.
Notch inhibition inhibits brain tumor stem cells and angiogenesis in an 
organotypic “explant” model of glioblastoma
Notch signaling is an evolutionarily well-conserved pathway that plays a key role in many aspects 
of development such as cell differentiation, proliferation, and apoptotic events, but the 
specific effects are highly context dependent 14,15. Importantly the Notch pathway plays a major 
role in maintenance of the stem cell state in the nervous system 16,17, and in the regulation of 
angiogenesis in normal development as well as tumors including glioblastoma 18–20. In chapter 
five we showed that notch inhibition by the γ-secretase inhibitor DAPT resulted in decreased 
proliferation and self-renewal of tumor cells in our explant system but was also associated with a 
decrease in endothelial cells. Interestingly, when we selectively eliminated endothelial cells from 
the explants via a toxin conjugate, we also observed a decrease in self-renewal of tumor stem cells 
giving support to the “niche” concept. Further analysis revealed that γ-secretase inhibition but 
not bevacizumab repressed the transition between CD133+ BTSC to endothelial progenitor cells 
9. To mimic the clinical setting we tested the combination treatment with Notch blockade and 
radiation. The combination treatment resulted in a substantial decrease in proliferation and in 
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self-renewal in tumor explants while radiation alone was less effective 13. This data suggests that 
the Notch pathway plays a critical role in linking angiogenesis and cancer stem cell self-renewal 
and is thus a potential therapeutic target.
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Valorisatie
Gliomen zijn tumoren die in de hersenen ontstaan en zijn een relatief zeldzame vorm van 
kanker. In Nederland krijgen ongeveer 1100 volwassen patiënten deze diagnose en bij ongeveer 
400 mensen gaat het om de meest kwaadaardige vorm glioblastoom. De prognose voor de 
kwaadaardige hersentumor glioblastoom blijft, ondanks de technologische en wetenschappelijke 
vooruitgang in de geneeskunde van de laatste 50 jaar, onveranderd slecht. De meeste patiënten 
overlijden na ongeveer 15 maanden en de impact die deze ziekte op patiënten en hun familie 
heeft is zeer groot. Veel van de huidig beschikbare chemotherapeutica hebben geen effect laten 
zien, ondanks dat in veel andere tumoren deze behandelingen wel effectief zijn gebleken. Dat 
komt waarschijnlijk doordat het lichaam de hersenen zeer goed beschermt tegen invloeden van 
buitenaf door de bloed-hersenbarrière wat in dit geval leidt tot minder goed doordringen van de 
behandeling in de hersenen. 
Een van de eerste observaties van wetenschappers die tumoren onderzochten halverwege de 
vorige eeuw was dat deze een toegenomen vaatgroei hadden. De gedachte die onderzoekers dan 
ook snel kregen was om deze vaatgroei, die de voeding voor de tumor aanlevert, te remmen. De 
naam voor deze toegenomen vaatgroei naar tumoren is angiogenese en is een proces dat ook in 
de embryologie voorkomt als het menselijk lichaam gevormd wordt. Angiogenese remming werd 
al snel populair als behandeling tegen kanker en de eerste experimenten in muizen waren ook 
zeer succesvol. Een van de belangrijkste eiwitten in het proces van angiogenese bleek Vascular 
Endothelial Growth Factor (VEGF) te zijn en remmers van dit eiwit konden tumoren in muizen 
zeer effectief behandelen. De verwachtingen voor deze behandeling bij patiënten was dan ook 
hooggespannen en zeker bij patiënten met een glioblastoom omdat dit een zeer vaatrijke tumor 
is. 
Sinds 2004 is de remmer van VEGF, die inmiddels de naam bevacizumab had gekregen, 
goedgekeurd voor de behandeling van verschillende vormen van kanker. De effectiviteit wisselde 
helaas sterk en bij de maligne hersentumor glioblastoom werd helaas geen toename in overleving 
gevonden bij grote gerandomiseerde studies. De patiënten hadden wel baat bij de behandeling 
omdat het langer duurde voordat de tumor progressie vertoonde en ook bleek dat door deze 
behandeling minder reactieve zwelling van het hersenweefsel optrad waardoor andere medicijnen 
om dit proces tegen te gaan minder nodig waren. Ook was de perceptie van veel neuro-oncologen 
dat sommige patiënten toch langdurig veel baat hadden van behandeling met bevacizumab. Deze 
observaties hebben ertoe geleid dat het een zeer gangbare behandeling voor patiënten met een 
glioblastoom in Amerika is, waarbij de tumor na de eerste behandelingen terugkomt. 
De laatste jaren is er zeer veel onderzoek gedaan naar het gebrek aan effectiviteit van angiogenese 
remming en zo erachter te komen hoe deze middelen efficiënter gebruikt kunnen worden. 
De hoop hierbij is dat in de toekomst patiënten vooraf geselecteerd kunnen worden zodat ze 
Chapter 7120 |
de hoogste kans hebben om te reageren om de beschikbare angiogenese remmers. Een van de 
belangrijkste ontdekking is dat het proces van angiogenese aanzienlijk ingewikkelder is dan 
aanvankelijk werd gedacht. Er zijn veel meer eiwitten bij het proces betrokken dan alleen VEGF 
en de omgeving van de tumor speelt een grote rol in de resistentie die vaak ontstaat zijn twee 
van de vele verklaringen die zijn gevonden. Het bleek ook dat de modellen die zijn gebruikt bij 
de eerdere succesvolle experimenten met VEGF remming geen goede correlatie hadden met 
tumoren bij patiënten. Desondanks blijft angiogenese een essentieel onderdeel bij het ontstaan 
van kanker. Als het lukt om hierin effectief te interveniëren zal dit zeker een gunstig effect hebben 
op de behandeling van de kanker en hersentumoren. De centrale hypothese van de thesis is 
derhalve: angiogenese remming in glioblastoom is een effectieve behandeling.
In hoofdstuk een wordt beschreven dat glioblastoom cellen na bestraling meer VEGF gaan 
uitscheiden. Dit kan duiden op een beschermmechanisme dat deze cellen gebruiken om te 
overleven en doet vermoeden dat bestaande behandelingen gecombineerd kunnen worden met 
een angiogenese remmer. In hoofdstuk twee wordt beschreven dat tumoren met een bepaald 
moleculair profiel een slechtere kans hebben om te reageren op de behandeling met een VEGF 
remmer. Dat is belangrijk voor patiënten omdat dit middel veel bijwerkingen heeft en daarom 
patiënten met deze specifieke tumoren beter geen VEGF remmer kunnen krijgen. Andere 
patiënten hebben dan waarschijnlijk meer kans om te reageren. 
In hoofdstuk drie wordt getoond dat de het proces waardoor bloedvaten worden gevormd 
in tumoren ingewikkelder is dan aanvankelijk werd gedacht. Het blijkt dat tumor cellen zelf 
soms eigenschappen hebben die lijken op stamcellen. Deze tumor stamcellen die vaak in de 
buurt van tumorvaten liggen kunnen dan bijdragen aan het vormen van bloedvaten en worden 
niet geremd door de meest gebruikte angiogenese remmers. In hoofdstuk 4 wordt een model 
beschreven om tumor weefsel te onderzoeken waarin dit proces goed onderzocht kan worden 
omdat de relatie tussen bloedvaten en tumorcellen zo goed mogelijk in stand wordt gehouden. In 
hoofdstuk 5 wordt vervolgens beschreven hoe een remmer van de tumor stamcellen (zogenaamde 
notch-remmer), de tumorstamcellen in het eerder beschreven model kan remmer en ook de 
bloedvatgroei remt. Hiermee is dus een potentieel nieuwe angiogenese remmer beschreven die 
beter zou kunnen werken bij patiënten in de kliniek. 
Concluderend wordt in deze thesis zowel klinisch als preklinisch de het proces van angiogenese 
en de meest gangbare angiogenese remmer bij patiënten met de kwaadaardige hersentumor 
glioblastoom onderzocht. Daarnaast wordt een alternatieve manier van bloedvatvorming in 
glioblastoom geponeerd met een nieuw, meer klinisch relevant onderzoek model. Een nieuwe 
remmer voor angiogenese wordt beschreven die potentieel veel patiënten in de praktijk met 
deze verschrikkelijke tumor kan helpen. Deze onderzoeken verdiepen en vullen de bestaande 
kennis over angiogenese bij glioblastoom aan, en gaan hopelijk leiden tot verbetering van de 
behandeling van deze verschrikkelijke tumor. 
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Summary
Taken together these findings highlight the complicated process that underlies angiogenesis in 
glioblastoma. The clinical challenges for the future will be to use this knowledge to overcome the 
therapeutic challenges to effectively use the angiogenesis inhibitors in the patients that will most 
likely respond to the treatment. Based on our data bevacizumab can inhibit the transformation 
from endothelial progenitor cells to endothelial cells, but has no influence the formation of 
endothelial progenitor cells from BTSC. It was possible to inhibit this step by a notch inhibitor 
that was found to be safe in a phase 0/1 trial21. It is therefore possible that notch inhibitors can 
augment bevacizumab to effectively inhibit angiogenesis in future trials. To test these hypotheses 
the organotypic “explant” system, that is ideally suited for these questions, can be used and may 
decrease the need for tests in animal models. The finding that EGFR amplification and classical 
subtype make glioblastoma less likely to respond to bevacizumab can be used to select patients 
on the basis of molecular characteristics of the tumor of the patient. Additional investigations 
are required to further validate this finding as well as to investigate the mechanistic basis for 
bevacizumab propensity to fail in the setting of amplified EGFR. One possibility is that EGFR 
amplified tumors have a higher percentage of endothelial cells that are derived from BTSC, 
but this remains to be proven. Despite the lack of effect of overall survival in trials to date, 
angiogenesis remains a hallmark of cancer and is considered a rate limiting step in carcinogenesis. 
To be able to effectively interfere in this process will have beneficial therapeutic effect, stand 
alone or in combination with cytotoxic treatments or immunotherapy, and is without a doubt 
worth the research effort.
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Nederlandse samenvatting
Samengevat laten de bevindingen in deze thesis het gecompliceerde proces dat aan angiogenese 
ten grondslag ligt zien. De klinische uitdaging voor de toekomst is om deze kennis toe te passen 
om effectief gebruik te maken van angiogenese remmers bij patiënten die de meeste kans hebben 
er goed op te reageren. Onze data laat zien dat de VEGF remmer bevacizumab de transformatie 
van voorloper endotheelcellen naar endotheelcellen kan remmer, maar geen effect heeft op de 
vorming van voorloper endotheelcellen door hersentumor stamcellen. Dit was wel mogelijk met 
een notch remmer die veilig was bevonden in een fase 0/1 trial 1. Het is daarom mogelijk dat notch 
remmers gecombineerd met bevacizumab effectiever angiogenese kan remmer in toekomstige 
trials. Om deze, en andere hypothesen te testen is het in dit proefschrift beschreven organotypic 
“explant” model erg geschikt en kan ervoor zorgen dat minder dierproeven nodig zijn. De 
bevinding dat EGFR amplificatie en glioblastomen met het “classical” subtype minder goed 
reageren op behandeling met bevacizumab kan gebruikt worden om patiënten te selecteren voor 
behandelingen op basis van moleculaire eigenschappen van de tumor. Verder onderzoek is nodig 
om deze bevindingen te bevestigen en om een mechanistische verklaring te vinden voor het falen 
van angiogenese remming bij tumoren met EGFR amplificatie. Een mogelijke verklaring is dat 
EGFR geamplificeerde tumoren meer endotheelcellen hebben die van hersentumorstamcellen 
afkomstig zijn, maar dit is nog niet bewezen. 
Ondanks het gebrek aan toename van overleving in trials met angiogenese remmers bij patiënten 
met een glioblastoom blijft dit proces een essentieel onderdeel bij het ontstaan van kanker. Als 
het lukt om effectief te interveniërend in dit proces, zal dat ongetwijfeld leiden tot een gunstig 
therapeutisch effect. Als alleenstaande behandeling of in combinatie met immunotherapie. Het 
is daarom zonder twijfel de wetenschappelijke inspanning waard. 
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Dankwoord
Dit proefschrift had er nooit kunnen komen zonder de hulp van zeer veel mensen, die ik allen 
zeer dankbaar ben. Desondanks wil ik er een paar uitlichten
First of all professor Tabar (chair department of neurosurgery MSKCC, New York). Dear Viviane, 
quite simply, I don’t think I would have published any paper (and consequently no thesis) if it 
wasn’t for your help. You have taught me to think academically at a higher level and to always 
be critical towards my own work. You have inspired me to keep trying to do better and come up 
with smarter solutions to the countless problems that we encountered in the laboratory and clinic 
in the years that we worked together in New York. I truly believe that you have made me a better 
researcher and clinician and I am forever grateful for that. 
Next I would like to thank professor Gutin (retired chair of department of Neurosurgery, MSKCC 
in New York). I could not have wished for a better role-model than you. The seemingly effortless 
way, in which you inspire people and shaped the absolute world class neurosurgical department 
at MSKCC is almost unbelievable. You have inspired me to become the best neurosurgeon I can 
possibly be and whenever I face a difficult problem I wonder how you would have handled it. I 
benefit every day from the excellent surgical training you gave in New York and I could not have 
wished for a better tutor. You give meaning to the phrase “lead by example” and I can only hope 
to one day, as a neurosurgeon, to be able to walk in your footsteps. 
Mijn promotor professor Temel. Beste Yasin, ik wil je hartelijk bedanken voor de manier waarop 
je me hebt opgevangen in Maastricht. Zonder jou, weet ik niet of ooit zou zijn gepromoveerd. 
Je aanstekelijke enthousiasme over onderzoek inspireert de gehele afdeling en gaat ongetwijfeld 
tot grote successen leiden. 
Dr. W van Furth en professor. Dr. L Stalper. Beste Lukas en Wouter. Dankzij jullie ben ik 
bij dit interessante onderzoeksgebied betrokken geraakt en heb ik wetenschappelijke stages 
in San Francisco en New York kunnen doen. Over de jaren hebben jullie me altijd de juiste 
adviezen gegeven en gemotiveerd om verder te gaan met onderzoek. Ik heb veel geleerd van jullie 
verschillende aanpak en doorzettingsvermogen en heb goede herinneringen aan de jaren dat we 
samen onderzoek deden met dr. J Verhoeff en dr M Donker. Zonder jullie zou dit proefschrift er 
zeker niet zijn waarvoor mijn oprechte dank. 
De leden van de beoordelingscommissie Professor Dr. Axl Zur Hausen, Proffesor Dr. C 
Dirven, Professor Dr. M. van Engeland Dr. D. Brandsma, Dr. L Ackermans, veel dank voor 
uw tijdsinvestering in het kritisch lezen van en beoordelen van mijn proefschrift, alsmede de 
bereidheid zitting te nemen in de beoordelingscommissie.
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The neurosurgical department at Memorial Sloan-Kettering cancer center. There are too many 
people I would like to thank here. Dr C. Brennan for his incredible teaching in tumor biology, dr 
Bilsky and dr Laufer for their leadership in spine surgery, all the lab workers, physician assistants, 
nurses, secretaries and scientific officers that I owe so much to. My sincere appreciation to you all. 
Beste stafleden van de afdeling neurochirurgie van het MUMC+, dank voor het warme welkom 
in Maastricht. Ik heb het hier erg naar mijn zin een van de belangrijkste voorwaarde daarvoor 
vind ik leuke collega’s. Ik zie ernaar uit om in de toekomst te blijven samen te werken. 
Mijn opleider professor Vandertop. Zonder u was ik nooit neurochirurg geworden en had ik 
nooit het fellowship in New York kunnen doen. Mijn oprechte dank hiervoor.
De neurochirurgische staf van het voormalig Academisch Medisch Centrum en het VU medisch 
centrum. Hartelijk dank voor de rol die jullie in mijn opleiding hebben gespeeld. Opleiden vind 
ik een van de belangrijkste en moeilijkste taken van een academisch medisch specialist. Ik wil 
jullie bedanken voor de moeite die jullie erin hebben gestoken. 
Mijn mede arts assistenten in het Academisch medisch centrum in Amsterdam. Ik wil jullie 
allen, en in het bijzonder dr. O van der Veer bedanken voor de samenwerking. Veel succes in de 
toekomst. 
Pappa en mamma. Hier zijn eigenlijk geen goede woorden voor. Ik wil jullie eigenlijk bedanken 
voor alles wat ik ooit in mijn leven heb bereikt. Alles hebben jullie mogelijk gemaakt en gesteund 
door de fantastische jeugd die ik heb gehad. Jullie hebben me altijd geliefd/ gesteund en veilig 
laten voelen. Jullie waren er altijd en stuurden me altijd zonder dwang de goede richting uit. Nu 
ik zelf kinderen heb zie ik pas goed in hoe verschrikkelijk moeilijk dat echt is. Pappa en mamma 
ik ben jullie voor alles ontzettend dankbaar. 
Mijn beste vrienden: Remco, Marvin, Niko, Daay, Bastiaan, Guido, Ivo, Bart en Mark. Jullie 
vriendschappen, sommige al bijna 35 jaar, zijn me ontzettend dierbaar. Alle leuke, en soms ook 
minder leuke, ervaringen heb ik met jullie kunnen delen. Zoveel fantastische herinneringen die 
we samen kunnen ophalen. Ik ben een gelukkiger mens dankzij jullie. 
Anne, Boris en Sem. Wat ben ik verschrikkelijk trots op jullie en geniet ik van hoe jullie opgroeien. 
Ik zou zo graag willen dat ik er vaker voor jullie zou zijn en jullie meer zou zien, maar ik geniet 
van elk moment dat we samen doorbrengen. Voor mij zijn jullie de belangrijkste mensen die er 
bestaan en ik zal er altijd voor jullie zijn. 
Tot slot, allerliefste Janneke. Mijn steun en toeverlaat. Zonder jouw steun en doorzettingsvermogen 
zou ik de laatste jaren nooit hebben volgehouden. Je positivisme en liefde hebben me door alle 
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moeilijke momenten heen gesleept en maakt het altijd tot een feest om weer samen te zijn. Ik 
wil met jou samen oud worden en genieten van wat we samen aan het opbouwen zijn. Ik hou 
ontzettend veel van je. 
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Koos Hovinga werd in Amstelveen geboren op 26 juni 1979. Hij groeide op in de Watergraafsmeer 
in Amsterdam waar hij na omzwervingen door heel Amsterdam, San Francisco en New York nu 
weer met zijn gezin woont. In 1991 startte hij op het Vossius gymnasium in Amsterdam waar 
hij in 1998 zijn diploma cum laude haalde. Na te zijn uitgeloot voor de studie geneeskunde 
studeerde hij in 1998 een jaar bewegingswetenschappen aan de VU in Amsterdam. In 1999 kon 
hij vanwege de cum laude regeling alsnog beginnen met de studie geneeskunde aan de Universiteit 
van Amsterdam. Tijdens zijn wetenschappelijke stage aan het einde van het 4de jaar geneeskunde 
deed hij onderzoek naar de kwaadaardige hersentumor glioblastoom in laboratorium voor 
experimentele radiotherapie in het Academisch Medisch Centrum. Voor zijn scriptie hierover 
ontving hij de scriptieprijs van de universiteit van Amsterdam in 2005. Naar aanleiding van dit 
onderzoek deed hij nog een aanvullende wetenschappelijke stage in het brain tumor center in 
San Francisco onder supervisie van professor Haas-Kogan. Na zijn co-schappen in 2006 besloot 
hij aanvullende wetenschappelijk ervaring op te doen aan het Memorial Sloan-Kettering cancer 
center (MSKCC) in New York. Na een clinical rotation op de afdeling neurochirurgie verbleef hij 
twee jaar in het laboratorium van professor Tabar waar hij zich verder verdiepte in de moleculaire 
biologie van glioblastomen. Na een succesvolle periode met onder andere een publicatie in het 
wereldberoemde tijdschrift Nature kon hij in 2009 beginnen met zijn opleiding Neurochirurgie 
in Amsterdam. Na afronding van zijn opleiding in 2015 keerde hij terug naar MSKCC voor een 
fellowship neuro-oncologische neurochirurgie. In dit zeer prestigieuze fellowship leerde hij onder 
supervisie van professor Gutin tumoren in de hersenen en het ruggenmerg te opereren. In 2016 
keerde hij terug naar Amsterdam waar hij als neurochirurg in het Slotervaart ziekenhuis en het 
Antoni van Leeuwenhoek ziekenhuis werkzaam was. Sinds 2019 is hij werkzaam in het Maastricht 
Universitair Medisch Centrum. Zijn primaire aandachtsgebieden zijn de schedelbasischirurgie 
en de oncologische neurochirurgie. 
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